

PubMed	Nucleotide	Protein	Genome	Structure	PMC	Taxonomy	OMIM	Books
Search PubMed	▼ for						Go	Clear
Limits Preview/Index History Clipboard Details								

Display	Abstract	▼	Show: 20	▼	Sort	▼	Send to	Text	▼
---------	----------	---	----------	---	------	---	---------	------	---

☐ 1: J Immunol Methods 1994 Apr 15;170(2):261-8

[Related Articles, Links](#)

Entrez PubMed

Production and characterization of monoclonal antibodies specific for the murine T cell receptor zeta chain.

van Oers NS, Teh SJ, Irving BA, Tiong J, Weiss A, Teh HS.

Howard Hughes Medical Institute, San Francisco, CA 94143-0724.

PubMed
Services

The T cell receptor (TCR) comprises an antigen-specific alpha beta heterodimer non-covalently associated with the CD3 gamma delta epsilon and TCR zeta subunits. Both the CD3 and TCR zeta subunits are proposed to be responsible for the intracellular signal-transduction events. We report here the production of eight monoclonal antibodies (mAbs) that bind in an ELISA assay to a 113 amino acid synthetic peptide corresponding to the cytoplasmic domain of TCR zeta. Western blot analysis of anti-CD8 precipitates of lysates of transfectants expressing chimeric CD8/zeta constructs encoding increasing COOH-terminal truncations of TCR zeta indicates that four of these mAbs recognized the region of TCR zeta chain comprising the last 29 COOH-terminal residues. Thus, this region of TCR theta may encode an immunodominant epitope. Furthermore, one of these mAbs, G3, is capable of precipitating both non-phosphorylated and tyrosine phosphorylated TCR zeta. The G3 mAb should be useful for elucidating the structural and signalling characteristics of the TCR zeta chain.


Related
Resources

PMID: 7512608 [PubMed - indexed for MEDLINE]

Display	Abstract	▼	Show: 20	▼	Sort	▼	Send to	Text	▼
---------	----------	---	----------	---	------	---	---------	------	---

[Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)
[Department of Health & Human Services](#)
[Freedom of Information Act](#) | [Disclaimer](#)

Feb 19 2003 14:38:47



PubMed	Nucleotide	Protein	Genome	Structure	PMC	Taxonomy	OMIM	Books	
Search	PubMed	▼	for					Go	Clear
Limits Preview/Index History Clipboard Details									

Display	Abstract	▼	Show: 20	▼	Sort	▼	Send to	Text	▼
---------	----------	---	----------	---	------	---	---------	------	---

☐ 1: Blood 1996 Jul 1;88(1):236-41

[Links](#)

Entrez PubMed

T cells from patients with Hodgkin's disease have a defective T-cell receptor zeta chain expression that is reversible by T-cell stimulation with CD3 and CD28.

Renner C, Ohnesorge S, Held G, Bauer S, Jung W, Pfitzenmeier JP, Pfreundschuh M.

PubMed
Services

Medical Department I, University of the Saarland, Homburg, Germany.



Related
Resources

To investigate the mechanisms underlying the deficiency of T lymphocytes from patients with Hodgkin's disease, we investigated the expression of the T-cell receptor (TCR) zeta chain in patients with Hodgkin's disease. By flow cytometry using an anti-zeta chain monoclonal antibody, peripheral blood T lymphocytes from patients with untreated Hodgkin's disease were shown to express decreased levels of the TCR zeta chain. After stimulation by combined CD3 and CD28 cross-linking, T cells from Hodgkin's disease patients upregulated zeta chain protein expression to normal values within 48 hours and achieved a cytolytic potential and levels of interleukin (IL)-2 secretion that were not different from T cells obtained from healthy controls. These results show that downregulation of the TCR zeta chain in Hodgkin's T lymphocytes is a reversible event. Costimulation of CD3 and CD28 is a novel approach for overcoming the T-cell deficiency in Hodgkin's disease and might be exploited clinically. As upregulation of the zeta chain can also be achieved using bispecific monoclonal antibodies (BI-MoAbs) with specificity for tumor antigens and CD3 and CD28, respectively, an immunotherapy with CD3/CD30 and CD28/CD30 Bi-MoAbs may overcome and should therefore, not be jeopardized by the inherent T-cell deficiency in patients with Hodgkin's disease.

PMID: 8704179 [PubMed - indexed for MEDLINE]

Display	Abstract	▼	Show: 20	▼	Sort	▼	Send to	Text	▼
---------	----------	---	----------	---	------	---	---------	------	---

[Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)
[Department of Health & Human Services](#)
[Freedom of Information Act](#) | [Disclaimer](#)

  Protein

PubMed	Nucleotide	Protein	Genome	Structure	PMC	Taxonomy	OMIM	Books
--------	------------	---------	--------	-----------	-----	----------	------	-------

Search for

☐ 1: AAA40900. T-cell receptor z...[gi:203386]



[BLink](#), [Links](#)

LOCUS AAA40900 164 aa linear ROD 22-JUL-1993
 DEFINITION T-cell receptor zeta chain.
 ACCESSION AAA40900
 VERSION AAA40900.1 GI:203386
 DBSOURCE locus RATCD3Z accession [L08447.1](#)
 KEYWORDS .
 SOURCE Rattus norvegicus (Norway rat)
 ORGANISM [Rattus norvegicus](#)
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;
 Rattus.
 REFERENCE 1 (residues 1 to 164)
 AUTHORS Farber,D.L., Giorda,R., Nettleton,M.Y., Trucco,M., Kochan,J.P. and
 Sears,D.W.
 TITLE Rat class III Fc gamma receptor isoforms differ in IgG
 subclass-binding specificity and fail to associate productively
 with rat CD3 zeta
 JOURNAL J. Immunol. 150 (10), 4364-4375 (1993)
 MEDLINE [93246650](#)
 PUBMED [8482840](#)
 COMMENT Method: conceptual translation.
 FEATURES Location/Qualifiers
 source 1..164
 /organism="Rattus norvegicus"
 /strain="Fisher F344"
 /db_xref="taxon:10116"
 /cell_line="CRNK-16"
 /cell_type="natural killer cell"
 Protein 1..164
 /product="T-cell receptor zeta chain"
 CDS 1..164
 /coded_by="L08447.1:47..541"
 /note="subunit of class III IgG Fc receptors"
 ORIGIN
 1 mkwtasvlac ilqvqfpgae aqsfglldpk lcymldgilf iygvivtaly lrakfsrsad
 61 aaaylqdpnq lynelnlgrr eeydvldkkp prdpemggkq qrrrnpqegv ynalqdkkma
 121 eayseigmkg errrgkghdg lyqglstatk dtydalhmqt lppr
 //

Revised: August 5, 2002.

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

Feb 19 2003 14:49:48

 	
PubMed Nucleotide Protein Genome Structure PMC Taxonomy OMIM Books	
Search <input type="text" value="Protein"/> for <input type="text"/> <input type="button" value="Go"/> <input type="button" value="Clear"/>	
Limits Preview/Index History Clipboard Details	
Display <input type="text" value="default"/> Show <input type="text" value="20"/> Send to <input type="text" value="File"/> <input type="button" value="Get Subsequence"/>	

1: A44266. protein-tyrosine ...[gi:346421]

[BLink](#), [Domains](#), [Links](#)

LOCUS A44266 619 aa linear PRI 19-DEC-1997
 DEFINITION protein-tyrosine kinase (EC 2.7.1.112) ZAP-70 - human.
 ACCESSION A44266
 VERSION A44266 GI:346421
 DBSOURCE pir: locus A44266;

summary: #length 619 #molecular-weight 69876 #checksum 8772
 ;
 genetic: #gene GDB:SRK; ZAP-70 ##cross-references GDB:433738;
 OMIM:176947 #map_position 4pter-4qter #note defects in this gene
 are associated with an autosomal recessive form of severe combined
 immunodeficiency (SCID)
 ;
 superfamily: protein-tyrosine kinase ZAP-70; protein kinase
 homology; SH2 homology
 ;
 PIR dates: 10-Jun-1993 #sequence_revision 18-Nov-1994 #text_change
 19-Dec-1997

KEYWORDS ATP; phosphotransferase; severe combined immunodeficiency; T-cell;
 tyrosine-specific protein kinase.

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (residues 1 to 619)

AUTHORS Chan,A.C., Iwashima,M., Turck,C.W. and Weiss,A.

TITLE ZAP-70: a 70 kd protein-tyrosine kinase that associates with the
 TCR zeta chain

JOURNAL Cell 71 (4), 649-662 (1992)

MEDLINE 93046663

PUBMED 1423621

FEATURES

source

Location/Qualifiers

1..619

/organism="Homo sapiens"

/db_xref="taxon:9606"

Protein

1..619

/product="protein-tyrosine kinase ZAP-70"

/EC_number="2.7.1.112"

Region

10..102

/region_name="domain"

/note="SH2 homology #label SH2A"

Region

163..254

/region_name="domain"

/note="SH2 homology #label SH2B"

Region

336..600

/region_name="domain"

/note="protein kinase homology #label KIN"

Region

344..352

/region_name="region"

/note="protein kinase ATP-binding motif"

ORIGIN

```
1 mdpdaahlpf fygsisraea eehklagma dglfllrqcl rslggyvls1 vhdvrfhhfp
61 ierqlngtya iaggkahcgp aelcefysrd pdglpcnlrk pcnrpsglep qpgvfdclrd
121 amvrdyvrqt wklegealeq aiisqapqve kliattaher mpwyhssltr eeaerklysg
181 aqtdgkfllr prkeqgtyal sliygktvyh ylisqdkagk ycipegtkfd tlwqlveylk
241 lkadgliycl keacpnssas nasgaaaptl pahpstlthp qrridtlnsd gytpeparit
301 spdkprpmpm dtsvyespys dpeelkdkkl flkrdnllia dielgcgnfg svrqqvyrmr
361 kkqidvaikv lkqgtekad t eemmreaqim hqldnpyivr ligvcqaeal mlvmemaggg
421 plhkflvgkr eeipvsnvae llhqvsmgmk yleeknfvhr dlaarnvllv nrhyakisdf
481 glskalgadd syytarsagk wplkwyap ec infrkfssrs dvwsygctmw ealsyggkpy
541 kkmkgpevma fieggkrmec ppecppelya lmsdcwi ykw edrpdfltve qrmracyysl
601 askvegppgs tqkaeaaca
```

//

Revised: August 5, 2002.

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

Feb 19 2003 14:49:48



PubMed	Nucleotide	Protein	Genome	Structure	PMC	Taxonomy	OMIM	Books
Search		Protein	for				Go	Clear
		Limits	Preview/Index		History		Clipboard	Details
Display	default	Show	20	Send to	File	Get Subsequence		

1: CAC41082. T cell receptor i...[gi:14330720]

[BLink](#), [Links](#)

LOCUS CAC41082 187 aa linear ROD 06-JUN-2001
 DEFINITION T cell receptor interacting molecule [Mus musculus].
 ACCESSION CAC41082
 VERSION CAC41082.1 GI:14330720
 DBSOURCE embl locus MMU297969, accession [AJ297969.1](#)
 KEYWORDS .
 SOURCE Mus musculus (house mouse)
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 REFERENCE 1
 AUTHORS Kirchgessner,H., Dietrich,J., Scherer,J., Isomaki,P., Korinek,V.,
 Hilgert,I., Bruyns,E., Leo,A., Cope,A.P. and Schraven,B.
 TITLE The transmembrane adaptor protein TRIM regulates T cell receptor
 (TCR) expression and TCR-mediated signaling via an association with
 the TCR zeta chain
 JOURNAL J. Exp. Med. 193 (11), 1269-1284 (2001)
 MEDLINE 21286433
 PUBMED 11390434
 REFERENCE 2 (residues 1 to 187)
 AUTHORS Bruyns,E.
 TITLE Direct Submission
 JOURNAL Submitted (21-NOV-2000) Bruyns E., Immunology, University of
 Heidelberg, Im Neuenheimer Feld 305, 69120 Heidelberg, GERMANY
 COMMENT Related sequence [AJ224878](#).
 FEATURES
 Location/Qualifiers
 source 1..187
 /organism="Mus musculus"
 /strain="C57/Bl6"
 /db_xref="taxon:10090"
 /tissue_type="spleen"
 /dev_stage="adult"
 Protein 1..187
 /product="T cell receptor interacting molecule"
 /function="unknown"
 CDS 1..187
 /gene="Trim"
 /coded_by="AJ297969.1:55..618"
 ORIGIN
 1 msgssgc pff lwgllaflgl alvislifni shyvekqrrd eiyrysddyi prvdeyyved
 61 apiygnleni ipepldency eqmkgrpqrs asdpqevaap aqvpaea qmc yasldhsvkg
 121 krrrprkqnt nvsdrgkdtq vytmdanvsq inmvesfppd ngvveesihd dparlfglir
 181 akrepvi
 //

Revised: August 5, 2002.

[Disclaimer](#) | [Write to the Help Desk](#)

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1644PNH

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Apr 08	"Ask CAS" for self-help around the clock
NEWS	3	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS	4	Apr 09	ZDB will be removed from STN
NEWS	5	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS	6	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS	7	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS	8	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS	9	Jun 03	New e-mail delivery for search results now available
NEWS	10	Jun 10	MEDLINE Reload
NEWS	11	Jun 10	PCTFULL has been reloaded
NEWS	12	Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS	13	Jul 22	USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS	14	Jul 29	Enhanced polymer searching in REGISTRY
NEWS	15	Jul 30	NETFIRST to be removed from STN
NEWS	16	Aug 08	CANCERLIT reload
NEWS	17	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS	18	Aug 08	NTIS has been reloaded and enhanced
NEWS	19	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS	20	Aug 19	IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS	21	Aug 19	The MEDLINE file segment of TOXCENTER has been reloaded
NEWS	22	Aug 26	Sequence searching in REGISTRY enhanced
NEWS	23	Sep 03	JAPIO has been reloaded and enhanced
NEWS	24	Sep 16	Experimental properties added to the REGISTRY file
NEWS	25	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS	26	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS	27	Oct 21	EVENTLINE has been reloaded
NEWS	28	Oct 24	BEILSTEIN adds new search fields
NEWS	29	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS	30	Oct 25	MEDLINE SDI run of October 8, 2002
NEWS	31	Nov 18	DKILIT has been renamed APOLLIT
NEWS	32	Nov 25	More calculated properties added to REGISTRY
NEWS	33	Dec 02	TIBKAT will be removed from STN
NEWS	34	Dec 04	CSA files on STN
NEWS	35	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS	36	Dec 17	TOXCENTER enhanced with additional content
NEWS	37	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS	38	Dec 30	ISMEC no longer available
NEWS	39	Jan 13	Indexing added to some pre-1967 records in CA/CAPLUS
NEWS	40	Jan 21	NUTRACEUT offering one free connect hour in February 2003
NEWS	41	Jan 21	PHARMAML offering one free connect hour in February 2003
NEWS	42	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS	43	Feb 13	CANCERLIT is no longer being updated
NEWS	44	Feb 24	METADEx enhancements

NEWS 45 Feb 24 PCTGEN now available on STN
NEWS 46 Feb 24 TEMA now available on STN

NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a,
CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:09:24 ON 25 FEB 2003

=> file medline embase biosis scisearch caplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 11:09:36 ON 25 FEB 2003

FILE 'EMBASE' ENTERED AT 11:09:36 ON 25 FEB 2003

COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 11:09:36 ON 25 FEB 2003

COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'SCISEARCH' ENTERED AT 11:09:36 ON 25 FEB 2003

COPYRIGHT (C) 2003 Institute for Scientific Information (ISI) (R)

FILE 'CAPLUS' ENTERED AT 11:09:36 ON 25 FEB 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> s zeta chain

L1 4147 ZETA CHAIN

=> s l1 and antibody

L2 1106 L1 AND ANTIBODY

=> s l2 and rat zeta chain

L3 1 L2 AND RAT ZETA CHAIN

=> d l3 cbib abs

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS

2000:53887 Document No. 132:106967 Immunological reagent specifically interacting with the extracellular domain of the human **zeta**

chain. Reiter, Christian (Connex G.m.b.H., Germany). PCT Int. Appl. WO 2000003016 A1 20000120, 79 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1999-EP4838 19990709. PRIORITY: EP 1998-112867 19980710.

AB The present invention relates to a nucleic acid mol. comprising a nucleic acid sequence encoding at least one complementary detg. region (CDR) of a variable region of an **antibody**, said **antibody** specifically interacting with the extracellular domain of the human **zeta-chain**, said **antibody** being obtainable by immunizing a rat with Jurkat cells and subsequently with a conjugate comprising a carrier mol. and a peptide comprising the 11 N-terminal amino acids of the **rat zeta-chain**. Preferably, the (poly)peptide encoded by the nucleic acid mol. of the invention is a monospecific or bispecific **antibody**. The invention also relates to pharmaceutical compns. comprising i.a. the nucleic acid mol. or **antibody** of the invention as well as to kits comprising the aforementioned compds. Finally, the invention relates to a method for the detn. of **zeta-chain** or eta-chain expression on NK-cells, T-cells or precursors thereof employing the **antibody** of the invention. The **antibodies** are useful for treatment and prevention of autoimmune diseases, immune deficiency, T cell malignancies, infectious diseases, and for suppression of immune response to avoid graft rejection after organ transplant.

=> s 11 and rat

L4 100 L1 AND RAT

=> s 14 and antibody

L5 39 L4 AND ANTIBODY

=> dup remove 15

PROCESSING COMPLETED FOR L5

L6 25 DUP REMOVE L5 (14 DUPLICATES REMOVED)

=> d 16 1-25 cib abs

'CIB' IS NOT A VALID FORMAT

In a multifile environment, a format can only be used if it is valid in at least one of the files. Refer to file specific help messages or the STNGUIDE file for information on formats available in individual files.

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):ab

L6 ANSWER 1 OF 25 CAPLUS COPYRIGHT 2003 ACS

AB The MRC OX52 monoclonal **antibody** is a marker of **rat** T lymphocytes. The authors have cloned by polymerase chain reaction the **rat** homolog of CD6, and fluorescein-activated cell sorter anal. and immunopptns. using OX52 in COS7 cells transfected with **rat** CD6 cDNA showed that CD6 is the cell-surface mol. recognized by OX52. Immunopptn. anal. showed that CD6 copptd. with CD5, which in turn, was copptd. equivalently with CD2, CD6, and the T cell receptor (TCR), but the fraction of CD5 assocd. with CD6 was highly phosphorylated in kinase assays, in marked contrast with the low level of phosphorylation of CD5 assocd. with TCR or CD2. Examn. of protein kinases assocg. with these antigens showed that paradoxically, CD2 copptd. the highest amt. of Lck and Fyn. CD6 also assocd. with Lck, Fyn, and ZAP-70, although at lower levels but addnl. copptd. the Tec family kinase Itk, which is absent from

CD2, CD5, and TCR complexes. Lck together with Itk was the best combination of kinases, effectively phosphorylating synthetic peptides corresponding to a cytoplasmic sequence of CD5. Overall, the results suggest that CD6 has an important role in the regulation of CD5 tyrosine phosphorylation, probably as a result of its unique feature of assocg. with kinases of different families.

L6 ANSWER 2 OF 25 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.

AB CTLA-4 negatively regulates TCR signaling, although the molecular basis for this effect has yet to be elucidated. The cytoplasmic YVKM motif, while binding to phosphatidylinositol 3-kinase, SHP-2 and the AP-1/AP-2 clathrin adaptor complexes, has been reported to play no role in CTLA-4 function. In contrast, in this study, we demonstrate that, although not essential, the YVKM motif contributes to optimal CTLA-4 blockage of TCR.zeta. or combined TCR.zeta. CD28 signaling. Significantly, dependency on the YVKM motif varied with the mode of anti-receptor presentation, where soluble **antibody** ligation was more dependent on the presence of the motif than immobilized **antibody**. Previous studies have mainly relied on the use of immobilized **antibody**. Neither SHP-2 binding, alterations in TCR.zeta. chain phosphorylation, nor ZAP-70 recruitment was involved in CTLA-4 wild-type or mutant inhibition. Overall, our findings clearly implicate the YVKM motif in optimal CTLA-4 function.

L6 ANSWER 3 OF 25 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.

AB The activation of protein tyrosine kinase(s) (PTK) is a critical event required for the development of NK cell-mediated cytotoxicity. Here we demonstrate that the adaptor protein shc undergoes tyrosine phosphorylation during the generation of **antibody**-dependent cellular cytotoxicity (ADCC) and natural killing. In addition, we report that, upon direct or **antibody**-dependent target cell interaction, shc coprecipitates with the Src homology 2 (SH2)-containing inositol phosphatase, SHIP. To gain information on the functional role of shc in NK cytotoxicity, we overexpressed wild-type or dominant negative shc constructs in the human NKL cell line. Our findings show a consistent shc-mediated down-regulation of ADCC and natural killing. Such functional effect correlates with a perturbation of the phosphoinositide (PI) metabolism by means of a shc-mediated negative regulation of inositol 1, 4, 5 triphosphate (IP3) generation and intracellular calcium flux upon CD16 ligation. Furthermore, our data show that dominant-negative shc-mediated perturbation of shc/SHIP interaction leads to inhibition of ligand-dependent SHIP recruitment to CD16 .zeta. chain . We suggest that shc plays a role of negative adaptor by modulating SHIP recruitment to activation receptors involved in the generation of NK cytotoxic function.

L6 ANSWER 4 OF 25 CAPLUS COPYRIGHT 2003 ACS

AB The present invention relates to a nucleic acid mol. comprising a nucleic acid sequence encoding at least one complementary detg. region (CDR) of a variable region of an **antibody**, said **antibody** specifically interacting with the extracellular domain of the human **zeta-chain**, said **antibody** being obtainable by immunizing a **rat** with Jurkat cells and subsequently with a conjugate comprising a carrier mol. and a peptide comprising the 11 N-terminal amino acids of the **rat zeta-chain** . Preferably, the (poly)peptide encoded by the nucleic acid mol. of the invention is a monospecific or bispecific **antibody**. The invention also relates to pharmaceutical compns. comprising i.a. the nucleic acid mol. or **antibody** of the invention as well as to kits comprising the aforementioned compds. Finally, the invention relates to a method for the detn. of **zeta-chain** or eta-chain expression on NK-cells, T-cells or precursors thereof employing the **antibody** of the invention. The **antibodies** are useful

for treatment and prevention of autoimmune diseases, immune deficiency, T cell malignancies, infectious diseases, and for suppression of immune response to avoid graft rejection after organ transplant.

L6 ANSWER 5 OF 25 MEDLINE

AB Immunoglobulin T-cell receptors (IgTCRs) combine the specificity of **antibodies** with the potency of cellular killing by grafting **antibody** recognition domains onto TCR signaling chains. IgTCR-modified T cells are thus redirected to kill tumor cells based on their expression of intact antigen on cell surfaces, bypassing the normal mechanism of activation through TCR-peptide-major histocompatibility complex (MHC) recognition. Melanoma is one of the most immunoresponsive of human cancers and has served as a prototype for the development of a number of immunotherapies. The target antigen for this study is the ganglioside GD3, which is highly expressed on metastatic melanoma with only minor immunologic cross-reaction with normal tissues. To determine an optimal configuration for therapy, four combinations of IgTCRs were prepared and studied: sFv-epsilon, sFv-zeta, Fab-epsilon, Fab-zeta. These were expressed on the surface of human T cells by retroviral transduction. IgTCR successfully redirected T-cell effectors in an MHC-unrestricted manner, in this case against a non-T-dependent antigen, with specific binding, activation, and cytotoxicity against GD3+ melanoma cells. Soluble GD3 in concentrations up to 100 microg/ml did not interfere with recognition and binding of membrane-bound antigen. Based on the outcomes of these structural and functional tests, the sFv-zeta construct was selected for clinical development. These results demonstrate key features that emphasize the potential of anti-GD3 IgTCR-modified autologous T cells for melanoma therapies.

L6 ANSWER 6 OF 25 CAPLUS COPYRIGHT 2003 ACS

AB ZAP-70 is another member of Syk family tyrosine kinases which plays an essential role in growth, differentiation, and function of T lymphocytes. In this study, we report the specific expression of a 66 kDa tyrosine kinase that is specifically cross-reacted with anti-ZAP-70 **antibodies** in the developing neurons. By immunoblot and immunopptn. assay using various anti-ZAP-70 **antibodies**, a 66 kDa tyrosine kinase was detected in lysates from **rat** brain. During the development of **rat** brain, expression levels of this 66 kDa tyrosine kinase were highest around 3 wk after birth and decreased thereafter in the adult. In addn., immunoblot anal. demonstrated that this 66 kDa tyrosine kinase was expressed almost solely in the nervous system. These results suggest that this ZAP-70-related tyrosine kinase may play an important role in growth and differentiation in the developing neurons. Our observations will provide the clue to approach the regulatory system common to neurogenesis and immune response.

L6 ANSWER 7 OF 25 CAPLUS COPYRIGHT 2003 ACS

AB Adoptive transfer of tumor cell-destroying cytotoxic T-lymphocytes which express on their surface .gtoreq.1 variant epitope encoded by the CD44 gene is a useful strategy in therapy of metastasizing tumors. The lymphocytes express a fusion protein which comprises (a) a portion having a specific affinity for an amino acid sequence encoded by a variant exon of the CD44 gene [e.g. a variable domain of an **antibody** to a variant CD44 (CD44v)] and (b) a subunit of the T-cell receptor complex or of an Ig receptor or portion thereof. Nucleic acids encoding such fusion proteins are used to transform the T-lymphocytes to expression of the fusion protein. Thus, cDNA fragments encoding the VH and V.kappa. domains of monoclonal **antibody** 1.1ASML (specific for an epitope expressed by variant exon v6 of the **rat** CD44 gene) were joined by a linker sequence, coupled at the 3' end to a truncated mouse .kappa.-chain cDNA, and expressed in a mouse permanent cytotoxic T-cell line. The fusion protein was integrated into the cell membrane through the transmembrane region of the TCR **.zeta.-chain**

signal peptide attached at the 5' end. I.v. injection of these cells into athymic nude mice bearing BSp73AS14 **rat** tumors suppressed growth of the tumors; this effect was enhanced by simultaneous i.p. administration of recombinant human IL-2.

L6 ANSWER 8 OF 25 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
AB Variant proteins of the CD44 surface glycoprotein family are expressed on many different human tumors and their lymph node metastases. An epitope encoded by sequences of variant exons CD44v7 and v8 and recognized by the monoclonal **antibody** VFF17 is frequently detected in cervical cancer, whereas the normal cervical epithelium lacks expression of this epitope. We have developed an immunotherapeutic approach for cervical cancer based on the expression of this CD44v7/8 epitope. The single chain antigen-binding fragment of VFF17 was fused to a signal transducing protein (**.zeta.-chain**) of the T-cell receptor complex (TCR) and was introduced into a retroviral gene transfer vector. Gene transfer was applied to the murine cytotoxic T-cell line c196. All recombinant clones expressed the fusion protein on their cell surface. Functionality of the recombinant fusion protein was tested by subjection of several recombinant clones to in vitro cytotoxicity assays. CD44v7/8-expressing target cells were killed efficiently by reprogrammed c196 in an MHC-independent fashion, whereas CD44v7/8-negative cells were not affected. These transfected T cell lines will now be tested in vivo using immune-deficient mice bearing CD44v7/8-expressing tumors.

L6 ANSWER 9 OF 25 MEDLINE DUPLICATE 1
AB We are developing strategies to use naive T lymphocytes in cancer therapy. For this purpose, we are deriving T cells with specificity of recognition for defined tumor cells. To direct effector lymphocytes toward tumor cells, we have manipulated the recognition specificity of naive **rat** and mouse T lymphocytes and a mouse T-cell line. The cells were stably transduced with a chimeric T-cell receptor (TCR) component. The **zeta chain** of the TCR consists of a single transmembrane protein with a short extracellular domain and an intracellular domain for TCR signaling. We provided an extracellular tumor cell recognition domain to the **zeta chain**. Human heregulin betal (ligand to the erbB-3 and erbB-4 receptors) and three different single-chain **antibodies** specific for the human and **rat** Neu/erbB-2 receptors were used. One single-chain **antibody** (C11) is directed against the **rat** Neu protein, and one single-chain **antibody** (FRP5) is directed against the human erbB-2 receptor. The single-chain **antibody** (R-AK) directed against the Mr 14,000 fusion protein of orthopox viruses served as a control. An efficient procedure was devised to introduce the chimeric genes into primary **rat** and mouse T lymphocytes. Retrovirus-producing packaging cell lines were cocultured with the T cells activated by phytohemagglutinin and interleukin 2. T-cell lines were transduced by exposure to retrovirus-containing supernatants from helper cell lines. Expression of the fusion genes was determined by fluorescence-activated cell sorting analysis. More than 80% of the naive **rat** and mouse T cells and 85-100% of the cells from the established T-cell lines expressed the fusion genes within 48 h after infection. The expression of the fusion genes was maintained for at least 10 days after infection. Target cells expressing Neu/erbB-2, erbB-3, or erbB-4 were lysed in vitro with high specificity by T cells expressing the corresponding recognition proteins. No selection of a marker gene is necessary to confer a predetermined recognition specificity. The described experiments are important for a gene therapy approach to cancer treatment with autologous T cells.

L6 ANSWER 10 OF 25 MEDLINE DUPLICATE 2
AB Variants of the CD44 protein family containing sequences encoded by variant exon 6 (v6) are involved in the metastatic spread of **rat**

and human tumors. The **rat**-specific **antibody** 1.1ASML, which recognizes a v6 epitope, interferes with metastatic dissemination of a **rat** pancreatic carcinoma. The single-chain antigen-binding fragment of this monoclonal **antibody** was fused to the **zeta-chain** of the T-cell receptor complex. The appropriate fusion gene was incorporated into a retroviral gene transfer vector. Murine cytotoxic T lymphocytes (CTLs) were infected, and cellular clones which express the single-chain **zeta-chain** fusion protein on their cell surface were selected. These CTLs are not MHC-restricted in their CD44v6 recognition and exhibit in vitro lytic activity toward cells expressing CD44 variants comprising exon v6. Tumor cell xenografts grown in athymic nude mice are suppressed in their growth upon infusion of the genetically manipulated CTLs. Our data indicate that the CD44v6 epitope is an effective target for immune tumor therapy and demonstrate the efficacy of genetically engineered CTLs in targeting tumors expressing such epitopes.

L6 ANSWER 11 OF 25 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
 AB CD3-epsilon and the **zeta-chain** of the bovine T-cell receptor (TCR) are two invariant molecules with an important role in signal transduction via the TCR/CD3 complex. The nucleotide sequence of a bovine CD3-epsilon cDNA clone containing the complete coding sequence was determined and the deduced amino acid (aa) sequence compared to that of other species. The cytoplasmic domains of the different CD3-epsilon clearly show a higher degree of conservation than the extracellular domains. Bovine CD3-epsilon produced in *Escherichia coli* using different bacterial expression vectors was recognised by **antibodies** (Ab) directed against the intracytoplasmic domain of human CD3-epsilon. A partial bovine TCR-**zeta-chain** cDNA was generated by the polymerase chain reaction (PCR) using primers that were based on sequences that are conserved between different species; 3' and 5' RACE-PCR were carried out to obtain the complete TCR-**zeta-chain** cDNA sequence. A comparison of the predicted TCR-**zeta-chain** aa sequence reveals that the GDP/GTP-binding motif, which is conserved in other species, shows marked differences in the bovine and ovine TCR-**zeta-chains**. In contrast to CD3-epsilon, the short also shows a high degree of identity. Ab were raised against the TCR-**zeta-chain**, produced as a glutathione S-transferase fusion protein in *E. coli*, and were used in Western blot analysis to further characterize TCR-**zeta-chain** expression in T-cells. These reagents provide valuable tools for the study of signal transduction pathways in normal and transformed bovine T-cells.

L6 ANSWER 12 OF 25 MEDLINE

L6 ANSWER 13 OF 25 SCISEARCH COPYRIGHT 2003 ISI (R)
 AB A cDNA encoding a signal transduction protein with a Src homology 2 (SH2) domain and a tyrosine phosphorylation site was cloned from a **rat** lymph node cDNA library. This protein, which we designate Lnk, has a calculated molecular weight of 33,988. When T lymphocytes were activated by **antibody**-mediated crosslinking of the T-cell receptor and CD4, Lnk became tyrosine phosphorylated. In activated T lymphocytes, phospholipase C gamma(1), phosphatidylinositol 3-kinase, and Grb-2 coimmunoprecipitated with Lnk. Our results suggest that Lnk becomes tyrosine phosphorylated and links the immediate tyrosine phosphorylation signals of the TCR to the distal phosphatidylinositol 3-kinase, phospholipase C gamma(1) and Ras signaling pathways through its multifunctional tyrosine phosphorylation site.

L6 ANSWER 14 OF 25 SCISEARCH COPYRIGHT 2003 ISI (R)
 AB In mast cells, antigen-mediated aggregation of the high-affinity receptor for immunoglobulin E, Fc epsilon RI, stimulates tyrosine phosphorylation and activation of multiple signaling pathways leading to

the release of several classes of mediators of the allergic response. Early events induced upon cross-linking of Fc epsilon RI include tyrosine phosphorylation of Fc epsilon RI subunits and activation of the tyrosine kinase p72(syk) (Syk), Which binds to tyrosine-phosphorylated Fc epsilon RI, Clustering of Syk, as a result of its interaction with aggregated Fc epsilon RI, may play a role in activating one or more of the signaling pathways leading to mediator release, To test this possibility, Syk was introduced into a model mast cell line (**rat** basophilic leukemia cells) as part of a chimeric transmembrane protein containing the extracellular and transmembrane domains of CD16 and CD7, respectively, Clustering of the Syk chimera, using **antibodies** against CD16, was found to be sufficient to stimulate early and late events normally induced by clustering of Fc epsilon RI, Specifically, aggregation of Syk induced degranulation, leukotriene synthesis, and expression of cytokine genes, Induction of mediator release was dependent on the kinase activity of Syk Consistent with this finding, clustering of Syk also induced the tyrosine phosphorylation of a profile of proteins, including phospholipase C-gamma 1 and mitogen-activated protein kinase, similar to that induced upon clustering of Fc epsilon RI, These results strongly suggest that Syk is an early and critical mediator of multiple signaling pathways that emanate from the Fc epsilon RI receptor and give rise to the allergic response.

L6 ANSWER 15 OF 25 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.

AB We studied the coupling of the TCR/CD3 complex to a T cell effector function, namely Fas-based T cell-mediated cytotoxicity. Encounter or re-encounter with antigen was mimicked by treating 5 d mixed lymphocyte culture cells or T cell hybridomas with anti-CD3 **antibody**. This TCR/CD3 engagement induced swift expression of Fas-based cytotoxicity in these cells. Induction of Fas-based cytotoxicity was Ca²⁺-dependent, while its execution was not; induction was sensitive to macromolecular synthesis inhibitors, in line with a demonstrable increase of the Fas ligand (Fas-L) message. We also used T cell hybridomas transfected with various constructs to dissect the involvement of distinct components of the TCR/CD3 complex. The cytoplasmic domain of the CD3 **.zeta**. **chain** was able to transduce by itself a signal leading to Fas-L expression, unless there were mutations in its activation receptor homology sequence 1 (ARH-1) motifs. On the one hand, these findings are relevant to signal transduction pathways coupled to the TCR/CD3, and on the other hand, to the involvement of Fas-based T cell-mediated cytotoxicity in various physiological and possibly pathophysiological situations.

L6 ANSWER 16 OF 25 SCISEARCH COPYRIGHT 2003 ISI (R)

AB Crosslinking of the B-cell receptor (BCR) for antigen to low-affinity receptors for IgG (Fc gamma RII) inhibits B-cell activation induced by BCR aggregation. The cell-triggering properties of the BCR depend on tyrosine-containing activation motifs (TAM), in the intracytoplasmic domain of its Ig alpha and Ig beta subunits. TAMs also account for the cell-triggering capabilities of the T-cell receptor (TCR) for antigen, in T lymphocytes, and of the high-affinity receptor for IgE (Fc epsilon RI), in mast cells. Using as a model, **rat** basophilic leukemia cells (RBL-2H3) stably transfected with cDNA encoding wild-type or mutated murine or human Fc gamma RIIB and chimeric molecules having the intracytoplasmic domain of the FcR gamma subunit or of TCR-CD3 zeta subunit, we found that the inhibitory properties of Fc gamma RII are neither restricted to B cells nor to BCR-dependent cell activation, but can be extended to other cells and, as a general rule, to TAM-dependent cell activation.

L6 ANSWER 17 OF 25 SCISEARCH COPYRIGHT 2003 ISI (R)

AB Aggregation of the high affinity IgE receptors (Fc epsilon RI) on **rat** basophilic leukemia RBL-2H3 cells results in protein tyrosine

phosphorylations. Previously we reported that there is prominent tyrosine phosphorylation of similar to 72-kDa proteins (pp72) and that the tyrosine kinase p72(syk) is one component of pp72. Here we studied further the relationship of p72(syk) to pp72. The aggregation of Fc epsilon RI induced the activation of p72(syk) which was parallel to its tyrosine phosphorylation. By in vitro kinase assay of immune complexes purified with anti-phosphotyrosine **antibodies**, p72(syk) was the major pp72 tyrosine kinase. However, by immunoblotting with anti-phosphotyrosine **antibodies**, p72(syk) was a minor component of pp72. The heterogeneous nature of pp72 was indicated by different studies. Under optimum conditions of one-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis, pp72 consisted of a heterogeneous group of 69-, 71-, and 72-kDa tyrosine-phosphorylated proteins. There were differences in the tyrosine phosphorylation of these proteins in cells activated in the absence of extracellular calcium or when stimulation was with the calcium ionophore A23187 or with phorbol myristate acetate. One of the proteins migrating at 69 kDa was p72(syk). By two-dimensional gel electrophoresis pp72 was found to consist of multiple tyrosine-phosphorylated proteins including 71-80-kDa proteins that associate with p53/56(lyn). A 75-kDa tyrosine-phosphorylated protein, different from pp72, was identified as p75(HS1) (SPY75). These results demonstrate the heterogeneous nature of the pp72 and that p72(syk) is activated after Fc epsilon RI aggregation.

L6 ANSWER 18 OF 25 SCISEARCH COPYRIGHT 2003 ISI (R)

AB Protein-tyrosine phosphorylation plays a critical role in the high-affinity IgE receptor (FcepsilonRI) signaling. Here we investigated the involvement of the tyrosine kinase p72syk in FcepsilonRI signaling in the **rat** mast cell line RBL-2H3. Specific **antibodies** were raised against peptides synthesized on the basis of the deduced peptide sequence of an essentially full-length **rat** syk cDNA. The expression of p72syk in RBL-2H3 cells was demonstrated with these **antibodies**. The aggregation of FcepsilonRI led to the tyrosine phosphorylation of p72syk that was detected after 15 s of stimulation, reached a plateau by 5 min, and was not induced by calcium influx or protein kinase C activation. Association of p72syk with the tyrosine phosphorylated FcepsilonRIgamma chain was detected only after receptor aggregation. We previously demonstrated that aggregation of the FcepsilonRI on mast cells results in the tyrosine phosphorylation of a 72-kDa protein (pp72) involved in IgE signaling. The depletion of p72syk from RBL-2H3 cell lysates resulted in only a slight decrease in the amount of pp72. These results demonstrate that pp72 is composed of several phosphoproteins and identify p72syk as one component of pp72. These data, together with recent observations in T cells, indicate that the interaction between p72syk-related tyrosine kinases and zeta-related proteins could play an important role in signal transduction.

L6 ANSWER 19 OF 25 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.DUPLICATE 3

AB Study of the T-cell repertoire in humans has been hampered by the lack of monoclonal **antibodies** (mAbs) to the T-cell receptor (TCR) variable region (V) gene products. We describe a method for producing mAbs to the human TCR .beta.- chain V (V(.beta.)) gene products in which mice were immunized with a **rat** basophil cell line (RBL-2H3) transfected with the extracellular domain of the TCR heterodimer fused to the **.zeta. chain** of CD3. These cells acted as excellent immunogens for raising anti-TCR mAb and also formed the basis of a rapid screening assay. We generated mAbs against V(.beta.) protein of the TCR, showed that these mAbs stained .simeq.1% of peripheral blood T cells, and further showed that the mAbs could stimulate proliferation of these T cells. We then characterized the mAbs by amplifying TCR cDNA derived from mAb-stimulated cells and sequencing the .beta. chain. All clones sequenced used the V(.beta.)7.1 chain, proving conclusively that the mAbs generated were specific for V(.beta.)7.1 subfamily. This method

generates mAbs to human TCR V(.beta.) proteins efficiently and might allow production of a complete panel of mAbs directed against human TCR V(.beta.) proteins.

L6 ANSWER 20 OF 25 SCISEARCH COPYRIGHT 2003 ISI (R)

AB Several new **rat** class III FcgammaR isoforms are described here, extending the genetic complexity of this receptor family and further distinguishing **rat** CD16 from mouse CD16, represented by only one receptor isoform, and human CD16, represented by only two isoforms. RNase protection assays reveal that three **rat** tumor cell lines-RBL-1 basophilic leukemia cells, RM-SV1 macrophages, and CRNK-16 NK cells-all coordinately express multiple and probably identical rtFcgammaRIII-related transcripts in similar relative proportions but at significantly different levels. These results indicate that no single isoform predominates in these cell types but that the overall level of rtFcgammaRIII-related transcripts is differentially regulated. Two of the rtFcgammaRIII isoforms found to have extensive amino acid sequence differences in their second extracellular (EC2) domains are shown to bind **rat** and mouse IgG subclasses differently. This result suggests that the receptor isoform diversity in this species may function as a mechanism for extending the IgG-binding capacity of **rat** leukocytes. Cloned cDNA for the **rat** CD3zeta protein was also isolated in this study and its ability to augment surface expression of class III FcgammaR was tested by rosetting of cDNA-transfected COS cells. Like the structurally homologous mouse CD3zeta, **rat** CD3zeta fails to promote surface expression of FcgammaRIII, sharply contrasting the efficient receptor expression produced by human CD3zeta. Variations in the transmembrane amino acid sequences correlate with the divergent capacities of these CD3zeta molecules to augment receptor expression. The high levels of CD3zeta message expressed in **rat** NK cells may indicate that other unidentified heterosubunits are required for assembly of **rat** CD3zeta into functional CD16 receptors.

L6 ANSWER 21 OF 25 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.

AB The coreceptor hypothesis postulates that physical association of CD4 with the TCR is required for effective signaling for T cell activation. A variety of studies has suggested that the coreceptor function of CD4 allows responses to 10- to 100-fold lower levels of peptide:self MHC class II ligand. We test the hypothesis of CD4 physical association with the TCR in two different ways. First, we use a panel of soluble **antibodies** directed at different TCR epitopes to activate a cloned T cell line, and show that activation by **antibodies** directed at a particular TCR epitope can be inhibited by anti-CD4 **antibodies** binding to a certain CD4 epitope. These effects establish that the interaction of CD4 and the TCR occurs in a specific orientation. Second, we use the same system to provide evidence that the physical association of CD4 with the TCR is required for effective tyrosine phosphorylation of the TCR . **zeta.-chain** subunit, presumably reflecting delivery of p56(lck) (lck) to the TCR. Only anti-TCR **antibodies** that induce physical association of CD4 with the TCR as monitored by cocapping can induce efficient tyrosine- phosphorylation of the TCR . **zeta.-chain**, unless second **antibodies** are used to force CD4 and the TCR to associate. Furthermore, the phosphorylation of the TCR . **zeta.-chain** exactly parallels physical association in time and drug sensitivity. We conclude from these studies that stimuli that drive physical association of CD4 and the TCR strongly favor T cell activation, supporting the coreceptor hypothesis of CD4 function.

L6 ANSWER 22 OF 25 MEDLINE DUPLICATE 4

AB The **zeta chain** of the T-cell antigen receptor is the prototype of a family of proteins that exist as disulfide-linked dimers and are subunits of the T-cell antigen receptor and both IgE and IgG binding Fc receptors. Two related genes encode the zeta and gamma

proteins. In this study we examine the ability of chimeric proteins consisting of the extracellular domain of the alpha chain of the interleukin 2 receptor (Tac) and the cytoplasmic domain of either zeta or gamma to activate cells when expressed in either T cells or **rat** basophilic leukemia cells. The zeta and gamma chimera were effective at eliciting interleukin 2 production in T cells and serotonin release in **rat** basophilic leukemia cells when externally cross-linked. Cytoplasmic-tail deletion mutants of zeta and gamma were constructed and used to verify the specificity of cell activation by these chimeric proteins. Signaling potencies of complementary mutants having the zeta tail truncated in position 108 or deleted from positions 66 through 114 suggested the presence of several functional domains in zeta.

L6 ANSWER 23 OF 25 SCISEARCH COPYRIGHT 2003 ISI (R)

AB In the present report, we demonstrated that modulation of CD26 from T cell surface induced by anti-CD26 (1F7) led to enhanced phosphorylation of CD3 zeta-tyrosine residues and increased CD4 associated p56lck tyrosine kinase activity. We further showed that CD26 was comodulated on the T cell surface with CD45, a known membrane-linked protein tyrosine phosphatase and that anti-CD26 was capable of precipitating CD45 from T cell lysates. These findings strongly suggest that CD26 may be closely associated with the CD45 protein tyrosine phosphatase on T cell surface and further support the notion that the interaction of CD26 with CD45 results in enhanced tyrosine kinase activity, **zeta-chain** phosphorylation, and T cell activation.

L6 ANSWER 24 OF 25 MEDLINE DUPLICATE 5

AB Crosslinking of CD2 antigen on T lymphocytes and natural killer (NK) cells leads to a rise in cytoplasmic-free Ca^{2+} concentration ($[Ca^{2+}]_i$). However, CD2 seems unlikely to interact directly with the second messenger pathways since signaling via CD2 is poor in T cells that lack the T cell receptor (TCR) and is absent in L cells or insect cells that express CD2. In contrast, NK cells that are also TCR- can be triggered via CD2, but it is unclear as to whether the CD16 Fc receptor (FcR) may facilitate this effect. The CD16 transmembrane molecule is expressed in a complex with the zeta homodimer or the zeta/gamma heterodimer and these dimers are also associated with the TCR complex. Thus, it seemed that **zeta chains** may provide the link between signaling on NK cells and T cells. This could be tested on TCR- cells since when CD16 is transfected into T cells it is expressed in a complex with TCR zeta homodimer or the zeta/gamma heterodimer. At first, potentiation of CD2 signaling was seen on TCR- Jurkat cells expressing CD16, but this was found to be dependent on trace levels (1%) of IgG in F(ab')₂ **antibody** preparations. With pure F(ab')₂, the effect was lost. Signaling on a **rat** NK cell line was also re-examined with F(ab')₂ **antibodies** that had no IgG contamination, and again no signal transduction via CD2 was seen. We thus conclude that there is no clear evidence for potent signaling via CD2 on cells that lack a TCR complex and that TCR **zeta chain** expressed at the cell surface is not sufficient to potentiate signaling via CD2 as measured by an increase in $[Ca^{2+}]_i$.

L6 ANSWER 25 OF 25 MEDLINE

AB The T-cell antigen receptor is a multisubunit complex consisting of at least seven chains. Based upon structural and genetic considerations, we have divided these chains into three groups. The alpha and beta subunits (Ti) are the clonotypic chains responsible for antigen recognition. Three chains that are invariant among all T-cells define the CD3 complex. These include the CD3 gamma, delta, and epsilon chains. The **zeta chain** is a distinct component that, like the CD3 chains, is invariant among all T-cells. In the majority of receptors, zeta is found as a disulfide-linked homodimer. We have recently shown that approximately 10% of zeta is disulfide-linked to a chain which we have called eta. A preliminary model has been proposed, suggesting that there are two

subclasses of receptors, depending upon the presence within the complex of either the zeta-zeta homodimer or the zeta-eta heterodimer. Evidence has been presented that these two subclasses may perform distinct signaling functions. In this paper the eta chain is characterized to determine whether it is structurally related to the **zeta chain** and, in particular, whether it might represent a post-translational modification of zeta. We can identify specific antigenic epitopes that are shared by both zeta and eta. However, not all **antibodies** raised against zeta can directly recognize eta. The apparent molecular mass of eta is 22 kDa, whereas zeta has a molecular mass of 16 kDa. We are unable to demonstrate any post-translational covalent modifications of eta to explain the difference in apparent molecular weight. These include phosphorylation, glycosylation, or sulfation. Amino acid incorporation studies demonstrate that the amino acid composition of eta is distinct from that of zeta. All of the eta in a T-cell is found in association with the rest of the components of the T-cell receptor. In addition, our anti-eta **antibodies** allow us to directly recognize human eta, which has an apparent molecular mass of approximately 23 kDa. Thus, eta and zeta appear to be related but distinct proteins, and we would propose that eta is the second member of the zeta group of components of the T-cell receptor.

```
=> s zeta chain DNA
L7          0 ZETA CHAIN DNA
```

```
=>
```

```
=> d his
```

```
(FILE 'HOME' ENTERED AT 11:09:24 ON 25 FEB 2003)
```

```
FILE 'MEDLINE, EMBASE, BIOSIS, SCISEARCH, CAPLUS' ENTERED AT 11:09:36 ON
25 FEB 2003
```

```
L1          4147 S ZETA CHAIN
L2          1106 S L1 AND ANTIBODY
L3           1 S L2 AND RAT ZETA CHAIN
L4          100 S L1 AND RAT
L5           39 S L4 AND ANTIBODY
L6          25 DUP REMOVE L5 (14 DUPLICATES REMOVED)
L7           0 S ZETA CHAIN DNA
```

```
=> s l1 and anti-zeta chain
L8           5 L1 AND ANTI-ZETA CHAIN
```

```
=> dup remove l8
PROCESSING COMPLETED FOR L8
L9           1 DUP REMOVE L8 (4 DUPLICATES REMOVED)
```

```
=> d l9 cbib abs
```

```
L9  ANSWER 1 OF 1      MEDLINE                                DUPLICATE 1
96290429 Document Number: 96290429.      PubMed ID: 8704179.      T cells from
patients with Hodgkin's disease have a defective T-cell receptor
zeta chain expression that is reversible by T-cell
stimulation with CD3 and CD28. Renner C; Ohnesorge S; Held G; Bauer S;
Jung W; Pfitzenmeier J P; Pfreundschuh M. (Medical Department I,
University of the Saarland, Homburg, Germany. ) BLOOD, (1996 Jul 1) 88 (1)
236-41. Journal code: 7603509. ISSN: 0006-4971. Pub. country: United
States. Language: English.
AB  To investigate the mechanisms underlying the deficiency of T lymphocytes
from patients with Hodgkin's disease, we investigated the expression of
the T-cell receptor (TCR) zeta chain in patients with
```

Hodgkin's disease. By flow cytometry using an **anti-zeta chain** monoclonal antibody, peripheral blood T lymphocytes from patients with untreated Hodgkin's disease were shown to express decreased levels of the TCR **zeta chain**. After stimulation by combined CD3 and CD28 cross-linking, T cells from Hodgkin's disease patients upregulated **zeta chain** protein expression to normal values within 48 hours and achieved a cytolytic potential and levels of interleukin (IL)-2 secretion that were not different from T cells obtained from healthy controls. These results show that downregulation of the TCR **zeta chain** in Hodgkin's T lymphocytes is a reversible event. Costimulation of CD3 and CD28 is a novel approach for overcoming the T-cell deficiency in Hodgkin's disease and might be exploited clinically. As upregulation of the **zeta chain** can also be achieved using bispecific monoclonal antibodies (BI-MoAbs) with specificity for tumor antigens and CD3 and CD28, respectively, an immunotherapy with CD3/CD30 and CD28/CD30 Bi-MoAbs may overcome and should therefore, not be jeopardized by the inherent T-cell deficiency in patients with Hodgkin's disease.

=> s l2 and rat zeta chain
L10 1 L2 AND RAT ZETA CHAIN

=> d l10 cbib abs

L10 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS

2000:53887 Document No. 132:106967 Immunological reagent specifically interacting with the extracellular domain of the human **zeta chain**. Reiter, Christian (Connex G.m.b.H., Germany). PCT Int. Appl. WO 2000003016 A1 20000120, 79 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1999-EP4838 19990709. PRIORITY: EP 1998-112867 19980710.

AB The present invention relates to a nucleic acid mol. comprising a nucleic acid sequence encoding at least one complementary detg. region (CDR) of a variable region of an **antibody**, said **antibody** specifically interacting with the extracellular domain of the human **zeta-chain**, said **antibody** being obtainable by immunizing a rat with Jurkat cells and subsequently with a conjugate comprising a carrier mol. and a peptide comprising the 11 N-terminal amino acids of the **rat zeta-chain**. Preferably, the (poly)peptide encoded by the nucleic acid mol. of the invention is a monospecific or bispecific **antibody**. The invention also relates to pharmaceutical compns. comprising i.a. the nucleic acid mol. or **antibody** of the invention as well as to kits comprising the aforementioned compds. Finally, the invention relates to a method for the detn. of **zeta-chain** or eta-chain expression on NK-cells, T-cells or precursors thereof employing the **antibody** of the invention. The **antibodies** are useful for treatment and prevention of autoimmune diseases, immune deficiency, T cell malignancies, infectious diseases, and for suppression of immune response to avoid graft rejection after organ transplant.

=> s l2 and human zeta chain
L11 2 L2 AND HUMAN ZETA CHAIN

=> dup remove l11

PROCESSING COMPLETED FOR L11

L12 2 DUP REMOVE L11 (0 DUPLICATES REMOVED)

=> d l12 1-2 cbib abs

L12 ANSWER 1 OF 2 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

2002:129949 Document No.: PREV200200129949. Co-expression of a CD19-specific immunoreceptor and CD28 in primary T-cells provides co-stimulation and augments efficacy in ALL and NHL. Topp, Max S. (1); Riddell, Stanley R. (1); Greenberg, Philip D. (1); Forman, Stephen J.; Raubitschek, Andrew; Jensen, Michael C.. (1) Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA USA. Blood, (November 16, 2001) Vol. 98, No. 11 Part 1, pp. 122a. <http://www.bloodjournal.org/>. print. Meeting Info.: 43rd Annual Meeting of the American Society of Hematology, Part 1 Orlando, Florida, USA December 07-11, 2001 ISSN: 0006-4971. Language: English.

AB Acute lymphoblastic leukemia (ALL) and high-grade Non-Hodgkin lymphomas (NHL) frequently recur following conventional chemotherapy or autologous/allogeneic stem cell transplant. Adoptive transfer of antigen-specific T-cell represents an attractive therapeutic modality for targeting minimal residual disease without the toxicity related to donor lymphocyte infusion. We took advantage of the tissue specific expression of CD19 during B-cell ontogeny and the availability of high-affinity **antibodies** to design a chimeric immunoreceptor consisting of the variable light and heavy regions of a CD19-specific monoclonal **antibody** fused to the human IgG4 Fc, the transmembrane region of human CD4 and as signaling domain the cytoplasmic portion of the **human zeta-chain**. A DNA construct encoding the chimeric immunoreceptor was introduced into primary human T-cells by plasmid transfection and chimeric immunoreceptor expressing CD4+ or CD8+ T-cell clones were selected by limiting dilution and screening for cytotoxicity against CD19+ targets. Clones with documented expression levels of the chimeric immunoreceptor in CD4+ and CD8+ T-cell clones demonstrated redirected specific lysis of CD19+ ALL and NHL cells. Strikingly, all cytolytic CD19-specific CD4+ and CD8+ T-cell clones were negative for the expression of CD28, a co-stimulatory molecule expressed in all naive T-cells but lost in 25-50% of CD8+ T-cells and a minor fraction of CD4+ memory T-cells. Engagement of CD28 cooperates with T-cell receptor signaling to enhance cytokine production, stabilize cytokine mRNA and induction of the antiapoptotic protein Bcl XL. The ligands for CD28, CD80 and CD86, are expressed at low levels by the majority of ALL and B-NHL cells. However, this low level of CD80 and CD86 expression can costimulate primary T-cells suggesting that expression of CD28 on T-cells may facilitate an effective antitumor response. Thus, CD28 was expressed into CD19-specific CD28-/CD4+ and CD8+ T-cell clones. The cytolytic potency of CD28+ CD19-specific CD4+ and CD8+ T-cell clones was maintained as measured by a 4-hr chromium release assay. In addition, target recognition by CD19 specific CD4+ and CD8+ T-cell clones engineered to express CD28 triggered production of IL-2 and resulted in robust autocrine proliferation. Conversely, no IL-2 production and autocrine proliferation was detected in the parental CD28- CD19-specific CD4+ and CD8+ T-cell clones. Preliminary results in treating NHL/Daudi-bearing NOD/SCID mice with adoptively transferred CD19-specific T-cells modified to express CD28 displayed augmented anti-tumor potency. Thus, the combined introduction of a CD19-specific chimeric immunoreceptor and CD28 into human CD4+ and CD8+ T-cells may augment the anti-tumor potency of adoptively transferred CD19-specific CD4+ and CD8+ T-cell clones in vivo.

L12 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS

2000:53887 Document No. 132:106967 Immunological reagent specifically interacting with the extracellular domain of the **human zeta chain**. Reiter, Christian (Connex G.m.b.H., Germany). PCT Int. Appl. WO 2000003016 A1 20000120, 79 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU,

CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1999-EP4838 19990709. PRIORITY: EP 1998-112867 19980710.

AB The present invention relates to a nucleic acid mol. comprising a nucleic acid sequence encoding at least one complementary detg. region (CDR) of a variable region of an **antibody**, said **antibody** specifically interacting with the extracellular domain of the **human zeta-chain**, said **antibody** being obtainable by immunizing a rat with Jurkat cells and subsequently with a conjugate comprising a carrier mol. and a peptide comprising the 11 N-terminal amino acids of the rat **zeta-chain**. Preferably, the (poly)peptide encoded by the nucleic acid mol. of the invention is a monospecific or bispecific **antibody**. The invention also relates to pharmaceutical compns. comprising i.a. the nucleic acid mol. or **antibody** of the invention as well as to kits comprising the aforementioned compds. Finally, the invention relates to a method for the detn. of **zeta-chain** or eta-chain expression on NK-cells, T-cells or precursors thereof employing the **antibody** of the invention. The **antibodies** are useful for treatment and prevention of autoimmune diseases, immune deficiency, T cell malignancies, infectious diseases, and for suppression of immune response to avoid graft rejection after organ transplant.

=> s l2 and mouse zeta-chain
L13 0 L2 AND MOUSE ZETA-CHAIN

=> s l2 and mouse zeta chain
L14 0 L2 AND MOUSE ZETA CHAIN

=> s mouse zeta chain
L15 0 MOUSE ZETA CHAIN

=> d his

(FILE 'HOME' ENTERED AT 11:09:24 ON 25 FEB 2003)

FILE 'MEDLINE, EMBASE, BIOSIS, SCISEARCH, CAPLUS' ENTERED AT 11:09:36 ON 25 FEB 2003

L1 4147 S ZETA CHAIN
L2 1106 S L1 AND ANTIBODY
L3 1 S L2 AND RAT ZETA CHAIN
L4 100 S L1 AND RAT
L5 39 S L4 AND ANTIBODY
L6 25 DUP REMOVE L5 (14 DUPLICATES REMOVED)
L7 0 S ZETA CHAIN DNA
L8 5 S L1 AND ANTI-ZETA CHAIN
L9 1 DUP REMOVE L8 (4 DUPLICATES REMOVED)
L10 1 S L2 AND RAT ZETA CHAIN
L11 2 S L2 AND HUMAN ZETA CHAIN
L12 2 DUP REMOVE L11 (0 DUPLICATES REMOVED)
L13 0 S L2 AND MOUSE ZETA-CHAIN
L14 0 S L2 AND MOUSE ZETA CHAIN
L15 0 S MOUSE ZETA CHAIN

=> s l1 and mouse
L16 1190 L1 AND MOUSE

=> s l16 and anti-zeta chain

L17 0 L16 AND ANTI-ZETA CHAIN

=> s (Reiter c?/au)

L18 622 (REITER C?/AU)

=> s l18 and zeta chain

L19 1 L18 AND ZETA CHAIN

=> d l19 cbib abs

L19 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS

2000:53887 Document No. 132:106967 Immunological reagent specifically interacting with the extracellular domain of the human **zeta chain**. **Reiter, Christian** (Connex G.m.b.H., Germany). PCT Int. Appl. WO 2000003016 A1 20000120, 79 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1999-EP4838 19990709. PRIORITY: EP 1998-112867 19980710.

AB The present invention relates to a nucleic acid mol. comprising a nucleic acid sequence encoding at least one complementary detg. region (CDR) of a variable region of an antibody, said antibody specifically interacting with the extracellular domain of the human **zeta-chain**, said antibody being obtainable by immunizing a rat with Jurkat cells and subsequently with a conjugate comprising a carrier mol. and a peptide comprising the 11 N-terminal amino acids of the rat **zeta-chain**. Preferably, the (poly)peptide encoded by the nucleic acid mol. of the invention is a monospecific or bispecific antibody. The invention also relates to pharmaceutical compns. comprising i.a. the nucleic acid mol. or antibody of the invention as well as to kits comprising the aforementioned compds. Finally, the invention relates to a method for the detn. of **zeta-chain** or eta-chain expression on NK-cells, T-cells or precursors thereof employing the antibody of the invention. The antibodies are useful for treatment and prevention of autoimmune diseases, immune deficiency, T cell malignancies, infectious diseases, and for suppression of immune response to avoid graft rejection after organ transplant.

=> s l18 and antibody

L20 155 L18 AND ANTIBODY

=> dup remove l20

PROCESSING COMPLETED FOR L20

L21 68 DUP REMOVE L20 (87 DUPLICATES REMOVED)

=> s l21 and zeta

L22 1 L21 AND ZETA

=> d l21 1-68 cbib

L21 ANSWER 1 OF 68 CAPLUS COPYRIGHT 2003 ACS

2001:284211 Document No. 134:307603 A rapid immunochromatographic assay for cell surface markers to detect acid-resistant microorganisms in the stool. **Reiter, Christian; Cullmann, Gerhard; Lakner, Meret; Truee, Andreas; Dehnert, Sonja; Schwartz, George** (Connex Gesellschaft zur Optimierung von Forschung und Entwicklung m.b.H., Germany). PCT Int. Appl. WO 2001027612 A2 20010419, 90 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE,

DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (German).
CODEN: PIXXD2. APPLICATION: WO 2000-EP10057 20001012. PRIORITY: EP 1999-120351 19991012; EP 2000-105592 20000316; EP 2000-107028 20000331; EP 2000-110110 20000510.

L21 ANSWER 2 OF 68 CAPLUS COPYRIGHT 2003 ACS
2000:842260 Document No. 134:13992 Albumin/spermidine/**antibody** mixture for neutralizing inhibitors of nucleic acid-modifying enzymes.
Reiter, Christian (Connex Gesellschaft zur Optimierung von Forschung und Entwicklung m.b.H., Germany). PCT Int. Appl. WO 2000071698 A2 20001130, 42 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (German). CODEN: PIXXD2. APPLICATION: WO 2000-EP3933 20000502. PRIORITY: DE 1999-19919942 19990430.

L21 ANSWER 3 OF 68 CAPLUS COPYRIGHT 2003 ACS
2000:314924 Document No. 132:331679 Detection of Helicobacter pylori and other acid-resistant microorganisms in stool using immunoassays.
Reiter, Christian; Cullmann, Gerhard; Friedrichs, Ulrike; Heppner, Petra; Lakner, Meret; Ringeis, Achim (Connex G.m.b.H., Germany). PCT Int. Appl. WO 2000026671 A1 20000511, 84 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (German). CODEN: PIXXD2. APPLICATION: WO 1999-EP8212 19991029. PRIORITY: EP 1998-120517 19981029; EP 1998-120687 19981106.

L21 ANSWER 4 OF 68 CAPLUS COPYRIGHT 2003 ACS
2000:84858 Document No. 132:150605 Anti-hepatitis c virus **antibody** and uses thereof. **Reiter, Christian; Habersetzer, Francois; Fournillier, Anne; Trepo, Christian; Desgranges, Claude; Inchauspe, Genevieve** (Connex Gesellschaft Zur Optimierung Von Forschung Und Entwicklung MbH, Germany; Institut National De La Sante Et De La Recherche Medicale (I.N.S.E.R.M.)). PCT Int. Appl. WO 2000005266 A1 20000203, 64 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1999-EP5173 19990720. PRIORITY: EP 1998-113595 19980721.

L21 ANSWER 5 OF 68 CAPLUS COPYRIGHT 2003 ACS
2000:53887 Document No. 132:106967 Immunological reagent specifically interacting with the extracellular domain of the human zeta chain.
Reiter, Christian (Connex G.m.b.H., Germany). PCT Int. Appl. WO 2000003016 A1 20000120, 79 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU,

AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1999-EP4838 19990709. PRIORITY: EP 1998-112867 19980710.

L21 ANSWER 6 OF 68 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
2001:210576 Document No.: PREV200100210576. A human monoclonal **antibody** recognizing different HCV genotypes suggesting convincing therapeutic potential. Barner, M. (1); Pueschke, S. (1); Ulferts, F. (1); Raum, T. (1); Inchauspe, G.; Dubuisson, J.; Diepolder, H. M.; **Reiter, C. (1)**; Mueller, H. M. (1). (1) Connex GmbH, Martinsried Germany. Immunobiology, (November, 2000) Vol. 203, No. 1-2, pp. 343-344. print. Meeting Info.: Joint Annual Meeting of the German and Dutch Societies of Immunology Dusseldorf, Germany November 29-December 02, 2000 ISSN: 0171-2985. Language: English. Summary Language: English.

L21 ANSWER 7 OF 68 SCISEARCH COPYRIGHT 2003 ISI (R)
1999:791091 The Genuine Article (R) Number: 244XA. Detection of humoral rejection in human cardiac allografts by assessing the capillary deposition of complement fragment C4d in endomyocardial biopsies. Behr T M (Reprint); Feucht H E; Richter K; **Reiter C**; Spes C H; Pongratz D; Uberfuhr P; Meiser B; Theisen K; Angermann C E. SMITHKLINE BEECHAM PHARMACEUT, DEPT CARDIOVASC PHARMACOL, 709 SWEELAND RD, POB 1539, UW 2510, KING OF PRUSSIA, PA 19406 (Reprint); UNIV MUNICH, KLINIKUM GROSSHADERN, DEPT CARDIOL, D-8000 MUNICH, GERMANY. JOURNAL OF HEART AND LUNG TRANSPLANTATION (SEP 1999) Vol. 18, No. 9, pp. 904-912. Publisher: MOSBY-YEAR BOOK INC. 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 . ISSN: 1053-2498. Pub. country: USA; GERMANY. Language: English.
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L21 ANSWER 8 OF 68 MEDLINE DUPLICATE 1
1999196580 Document Number: 99196580. PubMed ID: 10098944.
Three-dimensional reconstruction of the antennal lobe in *Drosophila melanogaster*. Laissue P P; **Reiter C**; Hiesinger P R; Halter S; Fischbach K F; Stocker R F. (Institute of Zoology and Program in Neuroscience, University of Fribourg, Switzerland.) JOURNAL OF COMPARATIVE NEUROLOGY, (1999 Mar 22) 405 (4) 543-52. Journal code: 0406041. ISSN: 0021-9967. Pub. country: United States. Language: English.

L21 ANSWER 9 OF 68 MEDLINE DUPLICATE 2
1999177089 Document Number: 99177089. PubMed ID: 10077484. A novel superoxide dismutase-based trap for peroxynitrite used to detect entry of peroxynitrite into erythrocyte ghosts. Macfadyen A J; **Reiter C**; Zhuang Y; Beckman J S. (Department of Pediatrics, Center for Free Radical Biology, University of Alabama at Birmingham, Birmingham, Alabama 35233, USA.) CHEMICAL RESEARCH IN TOXICOLOGY, (1999 Mar) 12 (3) 223-9. Journal code: 8807448. ISSN: 0893-228X. Pub. country: United States. Language: English.

L21 ANSWER 10 OF 68 MEDLINE DUPLICATE 3
1998018269 Document Number: 98018269. PubMed ID: 9378996. Depletion of CD8+ T lymphocytes by murine monoclonal CD8 **antibodies** and restored specific T cell proliferation in vivo in a patient with chronic hepatitis C. Kiefersauer S; **Reiter C**; Eisenburg J; Diepolder H M; Rieber E P; Riethmuller G; Gruber R. (Institute for Immunology, Klinikum Grosshadern, University of Munich, Germany.) JOURNAL OF IMMUNOLOGY, (1997 Oct 15) 159 (8) 4064-71. Journal code: 2985117R. ISSN: 0022-1767. Pub. country: United States. Language: English.

- L21 ANSWER 11 OF 68 MEDLINE DUPLICATE 4
 96225797 Document Number: 96225797. PubMed ID: 8642089. Treatment of severe cutaneous lupus erythematosus with a chimeric CD4 monoclonal **antibody**, cM-T412. Prinz J C; Meurer M; **Reiter C**; Rieber E P; Plewig G; Riethmuller G. (Department of Dermatology, Ludwig-Maximilians-University, Munich, FRG.) JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, (1996 Feb) 34 (2 Pt 1) 244-52. Journal code: 7907132. ISSN: 0190-9622. Pub. country: United States. Language: English.
- L21 ANSWER 12 OF 68 MEDLINE DUPLICATE 5
 96317110 Document Number: 96317110. PubMed ID: 8743291. Structural diversity of monoclonal CD4 **antibodies** and their capacity to block the HIV gp120/CD4 interaction. Weissenhorn W; Chen Y H; **Reiter C**; Federle C; Weiss E H; Riethmuller G; Rieber E P. (Institut fur Immunologie, Munchen, Germany.) HYBRIDOMA, (1996 Apr) 15 (2) 117-24. Journal code: 8202424. ISSN: 0272-457X. Pub. country: United States. Language: English.
- L21 ANSWER 13 OF 68 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
 1995:384458 Document No.: PREV199598398758. CD4, CD8 and CD 18 chimeric monoclonal **antibodies** (chim mAbs) with or without donor bone marrow transplantation for induction of tolerance after heart transplantation (HTx. Meiser, B. M.; Kreuzer, E.; **Reiter, C.**; Riethmueller, G.; Reichart, B.. Dep. Cardiac Surg., Inst. Immunol., Univ. Munich, Munich Germany. 9TH INTERNATIONAL CONGRESS OF IMMUNOLOGY.. (1995) pp. 650. The 9th International Congress of Immunology. Publisher: 9th International Congress of Immunology San Francisco, California, USA. Meeting Info.: Meeting Sponsored by the American Association of Immunologists and the International Union of Immunological Societies San Francisco, California, USA July 23-29, 1995 Language: English.
- L21 ANSWER 14 OF 68 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
 95259091 EMBASE Document No.: 1995259091. Restricted expression of the irrec-rst protein is required for normal axonal projections of columnar visual neurons. Schneider T.; **Reiter C.**; Eule E.; Bader B.; Lichte B.; Nie Z.; Schimansky T.; Ramos R.G.P.; Fischbach K.-F.. Institut fur Biologie III, Albert-Ludwigs-Universitat Freiburg,D-79104 Freiburg, Germany. Neuron 15/2 (259-271) 1995. ISSN: 0896-6273. CODEN: NERNET. Pub. Country: United States. Language: English. Summary Language: English.
- L21 ANSWER 15 OF 68 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
 1995:150530 Document No.: PREV199598164830. CD4, CD8 and CD 18 chimeric monoclonal **antibodies** (chim mAbs) with or without donor bone marrow transplantation for induction of tolerance after heart transplantation (HTx. Meiser, B. M. (1); Kreuzer, E.; **Reiter, C.**; Riethmueller, G.; Reichart, B.. (1) Dep. Cardiac Surg., Univ. Munich, Grosshadern Med. Center, 81366 Munich Germany. Journal of Heart and Lung Transplantation, (1995) Vol. 14, No. 1 PART 2, pp. S57. Meeting Info.: Fifteenth Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation San Francisco, California, USA April 5-8, 1995 ISSN: 1053-2498. Language: English.
- L21 ANSWER 16 OF 68 MEDLINE DUPLICATE 6
 95204958 Document Number: 95204958. PubMed ID: 7897241. A novel non-radioactive cellular cytotoxicity test based on the differential assessment of living and killed target and effector cells. Flieger D; Gruber R; Schlimok G; **Reiter C**; Pantel K; Riethmuller G. (Institute for Immunology, University of Munich, Germany.) JOURNAL OF IMMUNOLOGICAL METHODS, (1995 Mar 13) 180 (1) 1-13. Journal code: 1305440. ISSN: 0022-1759. Pub. country: Netherlands. Language: English.
- L21 ANSWER 17 OF 68 MEDLINE DUPLICATE 7

94353491 Document Number: 94353491. PubMed ID: 7915442. Chimeric monoclonal CD4 **antibody**--a novel immunosuppressant for clinical heart transplantation. Meiser B M; **Reiter C**; Reichenspurner H; Uberfuhr P; Kreuzer E; Rieber E P; Riethmuller G; Reichart B. (Department of Cardiac Surgery, Ludwig-Maximilians University of Munich, Germany.) TRANSPLANTATION, (1994 Aug 27) 58 (4) 419-23. Journal code: 0132144. ISSN: 0041-1337. Pub. country: United States. Language: English.

L21 ANSWER 18 OF 68 MEDLINE DUPLICATE 8
95170585 Document Number: 95170585. PubMed ID: 7866261. Treatment of endogenous uveitis with anti-CD4 monoclonal **antibody**: first report. Thureau S R; Wildner G; **Reiter C**; Riethmuller G; Lund O E. (University Eye Hospital, Section of Immunology, Munich, Germany.) GERMAN JOURNAL OF OPHTHALMOLOGY, (1994 Nov) 3 (6) 409-13. Journal code: 9206441. ISSN: 0941-2921. Pub. country: GERMANY: Germany, Federal Republic of. Language: English.

L21 ANSWER 19 OF 68 MEDLINE DUPLICATE 9
94174238 Document Number: 94174238. PubMed ID: 8128188. Treatment of rheumatoid arthritis with a chimeric CD4 monoclonal **antibody** (cM-T412): immunopharmacological aspects and mechanisms of action. van der Lubbe P A; **Reiter C**; Miltenburg A M; Kruger K; de Ruyter A N; Rieber E P; Bijl J A; Riethmuller G; Breedveld F C. (Department of Rheumatology, University Hospital Leiden, The Netherlands.) SCANDINAVIAN JOURNAL OF IMMUNOLOGY, (1994 Mar) 39 (3) 286-94. Journal code: 0323767. ISSN: 0300-9475. Pub. country: ENGLAND: United Kingdom. Language: English.

L21 ANSWER 20 OF 68 MEDLINE DUPLICATE 10
94030111 Document Number: 94030111. PubMed ID: 8216397. Chimeric CD4 monoclonal **antibody** cM-T412 as a therapeutic approach to rheumatoid arthritis. van der Lubbe P A; **Reiter C**; Breedveld F C; Kruger K; Schattenkirchner M; Sanders M E; Riethmuller G. (Department of Rheumatology, University Hospital Leiden, The Netherlands.) ARTHRITIS AND RHEUMATISM, (1993 Oct) 36 (10) 1375-9. Journal code: 0370605. ISSN: 0004-3591. Pub. country: United States. Language: English.

L21 ANSWER 21 OF 68 MEDLINE DUPLICATE 11
93174759 Document Number: 93174759. PubMed ID: 8438481. Selection and chimerization of a monoclonal CD4 **antibody** for heart transplantation. **Reiter C**; Meiser B M; Uberfuhr P; Wenke K; Reichenspurner H; Kreuzer E; Rieber E P; Riethmuller G; Reichart B. (Department of Cardiac Surgery, Ludwig-Maximilians University of Munich, Germany.) TRANSPLANTATION PROCEEDINGS, (1993 Feb) 25 (1 Pt 1) 788-9. Journal code: 0243532. ISSN: 0041-1345. Pub. country: United States. Language: English.

L21 ANSWER 22 OF 68 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. DUPLICATE 12
1993:333407 Document No.: PREV199345028132. CD4-**antibody** treatment of inflammatory bowel disease: One year follow up. Deusch, K.; Mauthe, B.; **Reiter, C.**; Riethmueller, G.; Classen, M.. II. Dep. Med., Technical Univ., Munich Germany. Gastroenterology, (1993) Vol. 104, No. 4 SUPPL., pp. A691. Meeting Info.: 94th Annual Meeting of the American Gastroenterological Association Boston, Massachusetts, USA May 15-21, 1993 ISSN: 0016-5085. Language: English.

L21 ANSWER 23 OF 68 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
1993:538589 Document No.: PREV199345125683. Treatment of cutaneous lupus erythematosus with a chimeric monoclonal CD4 **antibody**. Prinz, J. C.; Meurer, M.; **Reiter, C.**; Plewig, G.; Riethmueller, G.. Dep. Dermatol., Inst. Immunol., Univ. Munich, 80337 Munich Germany. Journal of Investigative Dermatology, (1993) Vol. 101, No. 3, pp. 446. Meeting Info.: Second Tricontinental Meeting of the JSID (Japanese Society for

Investigative Dermatology), SID (Society for Investigative Dermatology, Inc.), and ESDR (European Society for Dermatological Research) Kyoto, Japan October 28-31, 1993 ISSN: 0022-202X. Language: English.

- L21 ANSWER 24 OF 68 MEDLINE DUPLICATE 13
93222101 Document Number: 93222101. PubMed ID: 8466865. Effects of isotype and Fc region on in vitro function of a mouse/human chimeric CD4 **antibody**. Dalesandro M R; Pak K Y; Tam S; Wilson E; Looney J E; Knight D M; Ghayeb J; **Reiter C**; Rieber E P; Riethmuller G; +. (Centocor Inc., Malvern, PA 19355.) INTERNATIONAL IMMUNOLOGY, (1993 Mar) 5 (3) 283-91. Journal code: 8916182. ISSN: 0953-8178. Pub. country: ENGLAND: United Kingdom. Language: English.
- L21 ANSWER 25 OF 68 MEDLINE DUPLICATE 14
93213926 Document Number: 93213926. PubMed ID: 8461391. Human-murine chimeric CD4 monoclonal **antibodies**. A modern panacea for autoimmune disease?. Riethmuller G; Deusch K; Sanders M E; Dalesandro M R; Kiefersauer S; **Reiter C**; Rieber E P. (Institute for Immunology, University of Munich, Germany.) IMMUNOLOGY SERIES, (1993) 59 261-9. Ref: 17. Journal code: 0404721. ISSN: 0092-6019. Pub. country: United States. Language: English.
- L21 ANSWER 26 OF 68 MEDLINE DUPLICATE 15
93359724 Document Number: 93359724. PubMed ID: 8102628. Triple immunofluorescence flow cytometry, using whole blood, of CD4+ and CD8+ lymphocytes expressing CD45RO and CD45RA. Gruber R; **Reiter C**; Riethmuller G. (Institut fur Immunologie, Universitat Munchen, Germany.) JOURNAL OF IMMUNOLOGICAL METHODS, (1993 Aug 9) 163 (2) 173-9. Journal code: 1305440. ISSN: 0022-1759. Pub. country: Netherlands. Language: English.
- L21 ANSWER 27 OF 68 MEDLINE DUPLICATE 16
93314135 Document Number: 93314135. PubMed ID: 8324941. Anti-CD4 therapy in rheumatoid arthritis. van der Lubbe P A; **Reiter C**; Riethmuller G; Breedveld F C. (Department of Rheumatology, University Hospital, Leiden, The Netherlands.) CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, (1993 Mar-Apr) 11 Suppl 8 S151. Journal code: 8308521. ISSN: 0392-856X. Pub. country: Italy. Language: English.
- L21 ANSWER 28 OF 68 MEDLINE DUPLICATE 17
93066329 Document Number: 93066329. PubMed ID: 1438278. The monoclonal CD4 **antibody** M-T413 inhibits cellular infection with human immunodeficiency virus after viral attachment to the cell membrane: an approach to postexposure prophylaxis. Rieber E P; Federle C; **Reiter C**; Krauss S; Gurtler L; Eberle J; Deinhardt F; Riethmuller G. (Institute for Immunology, University of Munich, Federal Republic of Germany.) PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1992 Nov 15) 89 (22) 10792-6. Journal code: 7505876. ISSN: 0027-8424. Pub. country: United States. Language: English.
- L21 ANSWER 29 OF 68 MEDLINE DUPLICATE 18
93195869 Document Number: 93195869. PubMed ID: 1363476. Persistent depletion of CD4+ T cells and inversion of the CD4/CD8 T cell ratio induced by anti-CD4 therapy. Horneff G; Emmrich F; **Reiter C**; Kalden J R; Burmester G R. (Max Planck Clinical Research Group, Department of Medicine III, University of Erlangen-Nuremberg, Germany.) JOURNAL OF RHEUMATOLOGY, (1992 Dec) 19 (12) 1845-50. Journal code: 7501984. ISSN: 0315-162X. Pub. country: Canada. Language: English.
- L21 ANSWER 30 OF 68 MEDLINE DUPLICATE 19
93032289 Document Number: 93032289. PubMed ID: 1412816. A new chimeric monoclonal CD4 **antibody** for prevention of rejection after heart transplantation. Meiser B M; **Reiter C**; Ebel M; Uberfuhr P; Wenke

K; Reichenspurner H; Rieber E; Riethmuller G; Reichart B. (Department of Cardiac Surgery, Ludwig-Maximilians University of Munich, Germany.)
TRANSPLANTATION PROCEEDINGS, (1992 Oct) 24 (5) 1734. Journal code:
0243532. ISSN: 0041-1345. Pub. country: United States. Language: English.

L21 ANSWER 31 OF 68 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.DUPLICATE
20

1993:289378 Document No.: PREV199345007503. A new chimeric monoclonal CD4
antibody for heart (HTx) transplantation. Meiser, Bruno M. (1);
Reiter, Christian; Ueberfuhr, Peter (1); Wenke, Klaus (1);
Reichenspurner, Hermann (1); Rieber, Erich; Kreuzer, Eckhard (1);
Riethmuller, Gerd; Reichart, Bruno (1). (1) Dep. Cardiac Surgery,
Ludwig-Maximilians-Univ. Munich Germany. Circulation, (1992) Vol. 86, No.
4 SUPPL. 1, pp. I840. Meeting Info.: 65th Scientific Sessions of the
American Heart Association New Orleans, Louisiana, USA November 16-19,
1992 ISSN: 0009-7322. Language: English.

L21 ANSWER 32 OF 68 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

1992:359341 Document No.: BR43:37491. CHIMERIC MONOCLONAL ANTI-CD4
ANTIBODY THERAPY PROVES EFFECTIVE FOR TREATING INFLAMMATORY BOWEL
DISEASE. DEUSCH K; **REITER C**; MAUTHE B; RIETHMUELLER G; CLASSEN
M. DIGESTIVE DISEASE WEEK AND THE 93RD ANNUAL MEETING OF THE AMERICAN
GASTROENTEROLOGICAL ASSOCIATION, SAN FRANCISCO, CALIFORNIA, USA, MAY 9-15,
1992. GASTROENTEROLOGY. (1992) 102 (4 PART 2), A615. CODEN: GASTAB. ISSN:
0016-5085. Language: English.

L21 ANSWER 33 OF 68 SCISEARCH COPYRIGHT 2003 ISI (R)

92:234175 The Genuine Article (R) Number: HL846. TREATMENT OF
PSORIASIS-VULGARIS WITH A CHIMERIC MONOCLONAL CD4 **ANTIBODY**.
PRINZ J C (Reprint); GROSS B; **REITER C**; MEURER M; PRZYBILLA B;
RIETHMULLER G. UNIV MUNICH, DEPT DERMATOL, W-8000 MUNICH 2, GERMANY; UNIV
MUNICH, INST IMMUNOL, W-8000 MUNICH 2, GERMANY. JOURNAL OF INVESTIGATIVE
DERMATOLOGY (APR 1992) Vol. 98, No. 4, pp. 514. ISSN: 0022-202X. Pub.
country: GERMANY. Language: ENGLISH.

L21 ANSWER 34 OF 68 MEDLINE DUPLICATE 21

93077041 Document Number: 93077041. PubMed ID: 1446824. Combinatorial
functions of two chimeric **antibodies** directed to human CD4 and
one directed to the alpha-chain of the human interleukin-2 receptor.
Weissenhorn W; Scheuer W; Kaluza B; Schwirzke M; **Reiter C**;
Flieger D; Lenz H; Weiss E H; Rieber E P; Riethmuller G; +. (Institut fur
Immunologie, Universitat Munchen, Munich, Germany.) GENE, (1992 Nov 16)
121 (2) 271-8. Journal code: 7706761. ISSN: 0378-1119. Pub. country:
Netherlands. Language: English.

L21 ANSWER 35 OF 68 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V. .

92355606 EMBASE Document No.: 1992355606. From antilymphocyte serum to
therapeutic monoclonal **antibodies**: First experiences with a
chimeric CD4 **antibody** in the treatment of autoimmune disease.
Riethmuller G.; Rieber E.P.; Kiefersauer S.; Prinz J.; Van Der Lubbe P.;
Meiser B.; Breedveld F.; Eisenburg J.; Kruger K.; Deusch K.; Sanders M.;
Reiter C. Institut fur Immunologie, Universitat Munchen,
Goethestr. 31, 8000 Munchen 2, Germany. Immunological Reviews -/129
(81-104) 1992.
ISSN: 0105-2896. CODEN: IMRED2. Pub. Country: Denmark. Language: English.

L21 ANSWER 36 OF 68 SCISEARCH COPYRIGHT 2003 ISI (R)

92:699306 The Genuine Article (R) Number: JZ997. FROM ANTILYMPHOCYTE-SERUM TO
THERAPEUTIC MONOCLONAL-**ANTIBODIES** - 1ST EXPERIENCES WITH A
CHIMERIC CD4 **ANTIBODY** IN THE TREATMENT OF AUTOIMMUNE-DISEASE.
RIETHMULLER G (Reprint); RIEBER E P; KIEFERSAUER S; PRINZ J; VANDERLUBBE
P; MEISER B; BREEDVELD F; EISENBURG J; KRUGER K; DEUSCH K; SANDERS M;
REITER C. UNIV MUNICH, INST IMMUNOL, GOETHESTR 31, W-8000 MUNICH

2, GERMANY (Reprint); UNIV MUNICH, DERMATOL KLIN, W-8000 MUNICH 2, GERMANY; LEIDEN UNIV HOSP, DEPT INTERNAL MED, 2333 AA LEIDEN, NETHERLANDS; UNIV MUNICH, KLINIKUM GROSSHADERN, HERZCHIRURG KLIN, W-8000 MUNICH 70, GERMANY; KRANKENHAUS BARMHERZIGEN BRUDER, MUNCHEM, GERMANY; UNIV MUNICH, MED POLIKLIN, W-8000 MUNICH 2, GERMANY; TECH UNIV MUNICH, MED KLIN, W-8000 MUNICH 2, GERMANY; CENTOCOR INC, MALVERN, PA, 00000. IMMUNOLOGICAL REVIEWS (OCT 1992) Vol. 129, pp. 81-104. ISSN: 0105-2896. Pub. country: GERMANY; NETHERLANDS; USA. Language: ENGLISH.

L21 ANSWER 37 OF 68 MEDLINE DUPLICATE 22
 92310575 Document Number: 92310575. PubMed ID: 1614536. **Antibody** and HIV-1 gp120 recognition of CD4 undermines the concept of mimicry between **antibodies** and receptors. Davis S J; Schockmel G A; Somoza C; Buck D W; Healey D G; Rieber E P; **Reiter C**; Williams A F. (MRC Cellular Immunology Unit, Sir William Dunn School of Pathology, University of Oxford, UK.) NATURE, (1992 Jul 2) 358 (6381) 76-9. Journal code: 0410462. ISSN: 0028-0836. Pub. country: ENGLAND: United Kingdom. Language: English.

L21 ANSWER 38 OF 68 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
 1992:469964 Document No.: BR43:91314. A NEW CHIMERIC MONOCLONAL CD4 **ANTIBODY** FOR HEART HTX TRANSPLANTATION. MEISER B M; **REITER C**; EBEL M; UEBERFUHR P; WENKE K; REICHENSPURNER H; KREUZER E; RIETHMUELLER G; REICHART B. DEP. CARDIAC SURGERY, LUDWIG-MAXIMILIANS-UNIV. MUNICH.. XIVTH CONGRESS OF THE EUROPEAN SOCIETY OF CARDIOLOGY, BARCELONA, SPAIN, AUGUST 30-SEPTEMBER 1, 1992. EUR HEART J. (1992) 13 (ABSTR SUPPL), 72. CODEN: EHJODF. ISSN: 0195-668X. Language: English.

L21 ANSWER 39 OF 68 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
 1993:109742 Document No.: PREV199344052142. Evaluation of **antibody** mediated cellular cytotoxicity (ADCC) of cocktails of therapeutic monoclonal **antibodies** using the flowcytometric proportionality assay (FPA. Flieger, D. (1); Schlimok, G.; Gruber, R.; **Reiter, C.** ; Pantel, K.; Riethmuller, G.. (1) Inst. Immunol., Universitaet, 8000 Muenchen 2 Germany. Immunobiology, (1992) Vol. 186, No. 1-2, pp. 66. Meeting Info.: 23rd Meeting of the Society of Immunology Mainz, Germany October 28-31, 1992 ISSN: 0171-2985. Language: English.

L21 ANSWER 40 OF 68 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.DUPLICATE 23
 1993:40624 Document No.: PREV199344017474. Chimeric anti-CD4 monoclonal **antibody** M-T412 for prevention of rejection in liver transplantation: A pilot study. Hoffmann, R. M. (1); **Reiter, C.**; Soller, W.; Jung, M. C.; Zachoval, R.; Spengler, U.; Forst, H.; Pratschke, E.; Paumgartner, G.; et al.. (1) Dep. Internal Med. II, Klinikum Grosshadern, Inst. Immunol., Univ. Munich Germany. Hepatology, (1992) Vol. 16, No. 4 PART 2, pp. 57A. Meeting Info.: 43rd Annual Meeting and Postgraduate Course of the American Association for the Study of Liver Diseases, Chicago, Illinois, USA, October 31-November 3, 1992. HEPATOLOGY ISSN: 0270-9139. Language: English.

L21 ANSWER 41 OF 68 MEDLINE
 91304231 Document Number: 91304231. PubMed ID: 1677143. Chimaeric CD4 monoclonal **antibody** in treatment of generalised pustular psoriasis. Prinz J; Braun-Falco O; Meurer M; Daddona P; **Reiter C** ; Rieber P; Riethmuller G. LANCET, (1991 Aug 3) 338 (8762) 320-1. Journal code: 2985213R. ISSN: 0140-6736. Pub. country: ENGLAND: United Kingdom. Language: English.

L21 ANSWER 42 OF 68 MEDLINE DUPLICATE 24
 91222274 Document Number: 91222274. PubMed ID: 2025306. Treatment of rheumatoid arthritis with monoclonal CD4 **antibody** M-T151. Clinical results and immunopharmacologic effects in an open study,

including repeated administration. **Reiter C**; Kakavand B; Rieber E P; Schattenkirchner M; Riethmuller G; Kruger K. (Institute for Immunology, University of Munich, Germany.) ARTHRITIS AND RHEUMATISM, (1991 May) 34 (5) 525-36. Journal code: 0370605. ISSN: 0004-3591. Pub. country: United States. Language: English.

L21 ANSWER 43 OF 68 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.DUPLICATE 25
91230374 EMBASE Document No.: 1991230374. Chimaeric CD4 monoclonal **antibody** in treatment of generalised pustular psoriasis [18].
Prinz J.; Braun-Falco O.; Meurer M.; Daddona P.; **Reiter C**;
Rieber P.; Riethmuller G.. University Dermatology Clinic, Munich, Germany.
Lancet 338/8762 (320-321) 1991.
ISSN: 0140-6736. CODEN: LANCAO. Pub. Country: United Kingdom. Language: English.

L21 ANSWER 44 OF 68 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.DUPLICATE 26
1991:356601 Document No.: BR41:41116. EFFECTS OF ISOTYPE AND FC REGION ON IN-VITRO FUNCTION OF A MOUSE-HUMAN CHIMERIC CD4 **ANTIBODY**.
DALESANDRO M; PAK K Y; TAM S; WILSON E; **REITER C**; KNIGHT D;
GHRAYEB J L J; RIETHULLER G; DADDONA P. CENTOCOR INC., MALVERN, PA.. JOINT MEETING OF THE ASSOCIATION OF AMERICAN PHYSICIANS, THE AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, AND THE AMERICAN FEDERATION FOR CLINICAL RESEARCH, SEATTLE, WASHINGTON, USA, MAY 3-6, 1991. CLIN RES. (1991) 39 (2), 256A. CODEN: CLREAS. ISSN: 0009-9279. Language: English.

L21 ANSWER 45 OF 68 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
1992:110428 Document No.: BR42:50428. CHIMERIC MONOCLONAL CD4 **ANTIBODY** CM-T412 INDUCES LONG LASTING CD4 CELL DEPLETION IN RHEUMATOID ARTHRITIS RA PATIENTS. **REITER C**; VAN DER LUBBE P A; BREEDVELD F C; DADDONA P; KRUEGER K; KAKAVAND B; RIEBER P; RIETHMUELLER G. INST. IMMUNOL., UNIVERSITY, 8000 MUNICH, GER.. XXIIND MEETING OF THE SOCIETY OF IMMUNOLOGY, LUEBECK-TRAVEMUENDE, GERMANY, OCTOBER 23-26, 1991. IMMUNOBIOLOGY. (1991) 183 (3-4), 187. CODEN: IMMND4. ISSN: 0171-2985. Language: English.

L21 ANSWER 46 OF 68 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
1992:110424 Document No.: BR42:50424. TREATMENT OF RHEUMATOID ARTHRITIS RA WITH CHIMERIC CD4 MONOCLONAL **ANTIBODY**. VAN DER LUBBE P A; **REITER C**; RIETHMUELLER G; SANDERS M E; BREEDVELD F E. DEP. RHEUMATOL., UNIV. HOSP., LEIDEN, NETHERLANDS.. XXIIND MEETING OF THE SOCIETY OF IMMUNOLOGY, LUEBECK-TRAVEMUENDE, GERMANY, OCTOBER 23-26, 1991. IMMUNOBIOLOGY. (1991) 183 (3-4), 185. CODEN: IMMND4. ISSN: 0171-2985. Language: English.

L21 ANSWER 47 OF 68 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
1991:220831 Document No.: BR40:106666. TREATMENT OF RHEUMATOID ARTHRITIS WITH MURINE AND CHIMERIC HUMAN-MOUSE MONOCLONAL CD4 **ANTIBODIES**.
RIEBER E P; **REITER C**; KAKAVAND B; SCHATTENKIRCHNER M; KRUEGER K; DADDONA P; RIETHMUELLER G. INST. IMMUNOL., MED. POLIKLIN., UNIV. MUNICH, MUNICH, FRG.. MEETING ON MOLECULAR BIOLOGY AND THE IMMUNOPATHOGENESIS OF RHEUMATOID ARTHRITIS HELD AT THE 20TH ANNUAL MEETING OF THE KEYSTONE SYMPOSIA ON MOLECULAR AND CELLULAR BIOLOGY, LAKE TAHOE, CALIFORNIA, USA, MARCH 15-21, 1991. J CELL BIOCHEM SUPPL. (1991) 15 (PART E), 185. CODEN: JCBSD7. Language: English.

L21 ANSWER 48 OF 68 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
1991:220813 Document No.: BR40:106648. IN-VITRO EFFICACY OF MOUSE-HUMAN CHIMERIC CD4 **ANTIBODY** FUNCTIONAL CONTRIBUTIONS OF ISOTYPE AND FC. DALESANDRO M; PAK K Y; TAM S; WILSON E; **REITER C**; KNIGHT D; LOONEY J; GHRAYEB J; RIEBER E P; ET AL. CENTOCOR INC., MALVERN, PA.. MEETING ON MOLECULAR BIOLOGY AND THE IMMUNOPATHOGENESIS OF RHEUMATOID ARTHRITIS HELD AT THE 20TH ANNUAL MEETING OF THE KEYSTONE SYMPOSIA ON

MOLECULAR AND CELLULAR BIOLOGY, LAKE TAHOE, CALIFORNIA, USA, MARCH 15-21, 1991. J CELL BIOCHEM SUPPL. (1991) 15 (PART E), 179. CODEN: JCBSD7. Language: English.

L21 ANSWER 49 OF 68 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.DUPLICATE 27 91137730 EMBASE Document No.: 1991137730. Immunomodulation by monoclonal **antibodies** directed against cell adhesion molecules: A special case for CD4 monoclonal **antibodies**. Riethmuller G.; **Reiter** C.; Kakavand B.; Schattenkirchner M.; Kruger K.; Eisenburg J.; Rieber E.P.. Institute of Immunology, University of Munich, Munich, Germany. European Journal of Rheumatology and Inflammation 11/1 (177-181) 1991. ISSN: 0140-1610. CODEN: EJRIDH. Pub. Country: United Kingdom. Language: English. Summary Language: English.

L21 ANSWER 50 OF 68 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. 1992:110407 Document No.: BR42:50407. TREATMENT OF PSORIASIS VULGARIS WITH CD4 MONOCLONAL **ANTIBODY**. PRINZ J C; **REITER** C; DADDONA P; RIEBER E P; BRAUN-FALCO O; RIETHMUELLER G. DEP. DERMATOL., UNIVERSITY 8000 MUNICH, GER.. XXIIND MEETING OF THE SOCIETY OF IMMUNOLOGY, LUEBECK-TRAVEMUENDE, GERMANY, OCTOBER 23-26, 1991. IMMUNOBIOLOGY. (1991) 183 (3-4), 175. CODEN: IMMND4. ISSN: 0171-2985. Language: English.

L21 ANSWER 51 OF 68 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. 1992:18805 Document No.: BR42:6505. CHIMERIC MONOCLONAL CD4 **ANTIBODY** CM-T412 INDUCES A LONG LASTING CD4 CELL DEPLETION IN RHEUMATOID ARTHRITIS RA PATIENTS. **REITER** C; VAN DER LUBBE P A; BREEDVELD F C; DADDONA P; KRUGER K; KAKAVAND B; RIETHMUELLER G. INST. IMMUNOL., UNIV. MUNICH, GER.. 55TH ANNUAL MEETING OF THE AMERICAN COLLEGE OF RHEUMATOLOGY, BOSTON, MASSACHUSETTS, USA, NOVEMBER 17-21, 1991. ARTHRITIS RHEUM. (1991) 34 (9 SUPPL), S91. CODEN: ARHEAW. ISSN: 0004-3591. Language: English.

L21 ANSWER 52 OF 68 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. 1992:18794 Document No.: BR42:6494. TREATMENT OF RHEUMATOID ARTHRITIS WITH CHIMERIC CD4 MONOCLONAL **ANTIBODY**. VAN DER LUBBE P; **REITER** C; RIETHMUELLER G; SANDERS M E; BREEDVELD F C. DEP. RHEUMATOL., UNIV. HOSP., LEIDEN, NETHERLANDS.. 55TH ANNUAL MEETING OF THE AMERICAN COLLEGE OF RHEUMATOLOGY, BOSTON, MASSACHUSETTS, USA, NOVEMBER 17-21, 1991. ARTHRITIS RHEUM. (1991) 34 (9 SUPPL), S89. CODEN: ARHEAW. ISSN: 0004-3591. Language: English.

L21 ANSWER 53 OF 68 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. 1992:61205 Document No.: BR42:25105. HUMAN-ANTI-MOUSE-IMMUNOGLOBULIN RESPONSE IN THE COURSE OF ADJUVANT MONOCLONAL **ANTIBODY** TREATMENT WITH 17-1A IN PATIENTS WITH COLON CARCINOMA. GRUBER R; **REITER** C; FLIEGER D; HOECHTLEN-VOLLMAR W; RIETHMUELLER G. INSTITUT IMMUNOLOGIE MUENCHEN.. ELEVENTH BIENNIAL MEETING OF THE EUROPEAN ASSOCIATION FOR CANCER RESEARCH, GENOA, ITALY, NOVEMBER 3-6, 1991. EUR J CANCER. (1991) 27 (SUPPL 3), S53. CODEN: EJCAEL. ISSN: 0959-8049. Language: English.

L21 ANSWER 54 OF 68 MEDLINE 91014341 Document Number: 91014341. PubMed ID: 1976987. Monoclonal CD4 **antibodies** after accidental HIV infection. Rieber E P; **Reiter** C; Gurtler L; Deinhardt F; Riethmuller G. LANCET, (1990 Oct 20) 336 (8721) 1007-8. Journal code: 2985213R. ISSN: 0140-6736. Pub. country: ENGLAND: United Kingdom. Language: English.

L21 ANSWER 55 OF 68 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.DUPLICATE 28 90355537 EMBASE Document No.: 1990355537. Monoclonal CD4 **antibodies** after accidental HIV infection. Rieber E.P.; **Reiter** C.; Gurtler L.; Deinhardt F.; Riethmuller G.. Institute for Immunology, Ludwig Maximilian University, D-8000 Munich, Germany. Lancet 336/8721 (1007-1008) 1990. ISSN: 0140-6736. CODEN: LANCAO. Pub. Country: United Kingdom. Language:

English.

L21 ANSWER 56 OF 68 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
1991:130377 Document No.: BR40:62062. IN-VITRO AND IN-VIVO CHARACTERISTICS OF
A CHIMERIC HUMAN-MOUSE MONOCLONAL CD4 **ANTIBODY**. **REITER C**
; FEUCHT H; RIEBER E P; DALESANDRO M; GRAYEB J; DADDONA P; RIETHMUELLER G.
INST. IMMUNOL., UNIV. MUNICH, 8000 MUENCHEN, FRG.. XXI MEETING OF THE
SOCIETY OF IMMUNOLOGY, AACHEN, GERMANY, SEPTEMBER 12-16, 1990.
IMMUNOBIOLOGY. (1990) 181 (2-3), 219-220. CODEN: IMMND4. ISSN: 0171-2985.
Language: English.

L21 ANSWER 57 OF 68 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
1991:130274 Document No.: BR40:61959. DIFFERENTIAL MANIPULATION OF T CELL
FUNCTIONS BY A PANEL OF MONOCLONAL CD4 **ANTIBODIES**. **REITER**
C; PIRRON U; RIEBER E P. INST. IMMUNOL., GOETHESTR. 31, 8000 MUENCHEN
2, FRG.. XXI MEETING OF THE SOCIETY OF IMMUNOLOGY, AACHEN, GERMANY,
SEPTEMBER 12-16, 1990. IMMUNOBIOLOGY. (1990) 181 (2-3), 160. CODEN:
IMMND4. ISSN: 0171-2985. Language: English.

L21 ANSWER 58 OF 68 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
1991:63442 Document No.: BR40:28797. THERAPY OF RHEUMATOID ARTHRITIS WITH CD4
MONOCLONAL **ANTIBODIES**. WASSMER P; NEIDHART M; HINTERMANN U;
REITER C; RIEBER P; RIETHMUELLER P; FEHR K; WAGENHAUSER F J.
CLINIC RHEUMATOLOGY, UNIVERSITY HOSPITAL, ZURICH, SWITZ.. 54TH ANNUAL
MEETING OF THE AMERICAN COLLEGE OF RHEUMATOLOGY, SEATTLE, WASHINGTON, USA,
OCTOBER 27-NOVEMBER 1, 1990. ARTHRITIS RHEUM. (1990) 33 (9 SUPPL), S153.
CODEN: ARHEAW. ISSN: 0004-3591. Language: English.

L21 ANSWER 59 OF 68 MEDLINE DUPLICATE 29
90007498 Document Number: 90007498. PubMed ID: 2529203. Primary
peripheral T cell lymphoma in a kidney transplant under immunosuppression
with cyclosporine A. Ulrich W; Chott A; Watschinger B; **Reiter C**;
Kovarik J; Radaszkiewicz T. (Department of Pathology, University of
Vienna, Austria.) HUMAN PATHOLOGY, (1989 Oct) 20 (10) 1027-30. Journal
code: 9421547. ISSN: 0046-8177. Pub. country: United States. Language:
English.

L21 ANSWER 60 OF 68 MEDLINE DUPLICATE 30
90026733 Document Number: 90026733. PubMed ID: 2572230. Anti-CD4
antibody treatment of patients with rheumatoid arthritis: I.
Effect on clinical course and circulating T cells. Herzog C; Walker C;
Muller W; Rieber P; **Reiter C**; Riethmuller G; Wassmer P;
Stockinger H; Madic O; Pichler W J. (Department of Rheumatology and
Immunology, University of Basle, Switzerland.) JOURNAL OF AUTOIMMUNITY,
(1989 Oct) 2 (5) 627-42. Journal code: 8812164. ISSN: 0896-8411. Pub.
country: ENGLAND: United Kingdom. Language: English.

L21 ANSWER 61 OF 68 MEDLINE DUPLICATE 31
89274493 Document Number: 89274493. PubMed ID: 2659112. Removal of
neuroblastoma cells from bone marrow by a direct monoclonal
antibody rosetting technique. Berthold F; Schumacher R; Schneider
A; Bosslet K; **Reiter C**. (Children's Hospital, University of
Cologne, FRG.) BONE MARROW TRANSPLANTATION, (1989 May) 4 (3) 273-8.
Journal code: 8702459. ISSN: 0268-3369. Pub. country: ENGLAND: United
Kingdom. Language: English.

L21 ANSWER 62 OF 68 MEDLINE DUPLICATE 32
90038571 Document Number: 90038571. PubMed ID: 2809224. Deposition of
complement activation products on plastic-adsorbed immunoglobulins. A
simple ELISA technique for the detection of defined complement
deficiencies. Zwirner J; Felber E; **Reiter C**; Riethmuller G;
Feucht H E. (Institute for Immunology, University of Munich, F.R.G.)
JOURNAL OF IMMUNOLOGICAL METHODS, (1989 Nov 13) 124 (1) 121-9. Journal

code: 1305440. ISSN: 0022-1759. Pub. country: Netherlands. Language: English.

- L21 ANSWER 63 OF 68 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
1989:235683 Document No.: BR36:114167. SYNERGISTIC COMPLEMENT ACTIVATION BY PAIRS OF ANTI-CD4 MAB'S. **REITER C**; FEDERLE C; RIEBER P. INST. IMMUNOL., UNIV. MUNICH, MUNICH, W. GER.. 4TH INTERNATIONAL CONFERENCE ON HUMAN LEUCOCYTE DIFFERENTIATION ANTIGENS, VIENNA, AUSTRIA, FEBRUARY 21-25, 1989. TISSUE ANTIGENS. (1989) 33 (2), 99. CODEN: TSANA2. ISSN: 0001-2815. Language: English.
- L21 ANSWER 64 OF 68 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.DUPLICATE 33
1989:152259 Document No.: BR36:74300. IMMUNOPHARMACOLOGICAL ASPECTS OF THE TREATMENT WITH MONOCLONAL CD4 **ANTIBODIES**. **REITER C**; FEDERLE C; FEUCHT H; HELD E; SCHATTEKIRCHNER M; RIETHMUELLER G; RIEBER E P. INST. IMMUNOL., UNIV. MUENCHEN, 8000 MUENCHEN, W. GER.. XXTH MEETING OF THE SOCIETY OF IMMUNOLOGY, DUESSELDORF, WEST GERMANY, OCTOBER 6-8, 1988. IMMUNOBIOLOGY. (1988) 178 (1-2), 158-159. CODEN: IMMND4. ISSN: 0171-2985. Language: English.
- L21 ANSWER 65 OF 68 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.DUPLICATE 34
1987:455117 Document No.: BR33:103688. DIRECT MONOCLONAL **ANTIBODY** ROSETTING TECHNIQUE DART AN EFFECTIVE METHOD FOR BONE MARROW PURGING. RIEBER E P; WILHELM M; PECHUMER H; HAAS R; **REITER C**; RANK G; RIETHMUELLER G. INST. IMMUNOLOGY, UNIV. MUNICH, GOETHESTR. 31, D-8000 MUNICH, FRG.. FIRST INTERNATIONAL WORKSHOP ON BONE MARROW PURGING, ORLANDO, FLORIDA, USA, FEBRUARY 13-14, 1987. BONE MARROW TRANSPLANT. (1987) 2 (SUPPL 2), 139. CODEN: BMTRE9. Language: English.
- L21 ANSWER 66 OF 68 MEDLINE DUPLICATE 35
86166543 Document Number: 86166543. PubMed ID: 2420699. Protection of mice against tetanus toxin by combination of two human monoclonal **antibodies** recognizing distinct epitopes on the toxin molecule. Ziegler-Heitbrock H W; **Reiter C**; Trenkmann J; Futterer A; Riethmuller G. HYBRIDOMA, (1986 Spring) 5 (1) 21-31. Journal code: 8202424. ISSN: 0272-457X. Pub. country: United States. Language: English.
- L21 ANSWER 67 OF 68 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.DUPLICATE 36
1986:57485 Document No.: BR30:57485. HUMAN MONOCLONAL **ANTIBODIES** AGAINST TETANUS TOXIN CONSTRUCTION OF A BICLONAL COCKTAIL PROTECTING MICE AGAINST LETHAL DOSES OF TETANUS TOXIN. ZIEGLER-HEITBROCK H W L; **REITER C**; TRENKMAN J; FUETTERER A; RIETHMUELLER G. INST. IMMUNOL., UNIV. MUENCHEN, FRG.. 17TH MEETING OF THE GESELLSCHAFT FUER IMMUNOLOGIE (SOCIETY OF IMMUNOLOGY), GOETTINGEN, WEST GERMANY, SEPT. 25-28, 1985. IMMUNOBIOLOGY. (1985) 170 (1-2), 114. CODEN: IMMND4. ISSN: 0171-2985. Language: English.
- L21 ANSWER 68 OF 68 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.DUPLICATE 37
1984:86867 Document No.: BR27:3359. ESTABLISHMENT OF HUMAN-HUMAN B CELL HYBRIDOMAS PRODUCING MONO CLONAL **ANTIBODIES**. ZIEGLER-HEITBROCK H W L; **REITER C**; TRENKMAN J; RIETHMUELLER G. INST. FOR IMMUNOL., SCHILLERSTR. 42, 8000 MUENCHEN 2, FRG.. 15TH MEETING OF THE SOCIETY OF IMMUNOLOGY, BERLIN, WEST GERMANY, OCT. 5-8, 1983. IMMUNOBIOLOGY. (1983) 165 (3-4), 383. CODEN: IMMND4. ISSN: 0171-2985. Language: English.

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	193.88	194.09
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-5.21	-5.21

STN INTERNATIONAL LOGOFF AT 11:18:28 ON 25 FEB 2003